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ABSTRACT
METAL-ORGANIC FRAMEWORKS AS BACTERIA MIMICKING DELIVERY
SYSTEMS FOR TUBERCULOSIS
AILIN GUO
2021
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M.tb),
with an estimated 1.5 million deaths and 10 million infections each year. Although TB
can be effectively treated with antibiotics, because of the complications and length of
treatment, many people fail to complete the treatment which exacerbates the emergence
of drug-resistant M. tb strains. The goal of this work is to develop biomimetic particles as
host-directed therapy to target the infected macrophages. Two types of metal-organic
frameworks (MOFs), MIL-100(Fe) and MIL-88A(Fe) were developed for bacteriamimicking particles. As a proof-of-concept, Mannose was selected as a ligand to target
macrophages because many pathogens express mannose on the surface. MOFs were
successfully modified with mannose via EDC/NHS coupling method. No difference was
observed in cell uptake between MIL-100(Fe) and mannose-MIL-100(Fe). MannoseMIL-88A(Fe) showed a significant increase in macrophage uptake compared to its
unmodified counterpart. MIL-88A(Fe) is rod-shaped and has a size similar to M. tb
making it a natural platform for mycobacteria mimicking. MIL-88A(Fe) was coated with
two-layer hybrid lipids and mycolic acid (MA), the most abundant lipid in mycobacteria
cell wall, was also incorporated. The coating was confirmed by transmission electron
microscopy with energy dispersive x-ray analysis (TEM-EDX). Lipids coated MIL88A(Fe) with MA directly extracted from Mycobacterium. Avium exhibited the highest

xxvi
cell uptake compared to lipids coated MIL-88A(Fe) with commercial MA or without MA.
As MIL-100(Fe) is readily taken by macrophages, unlike MIL-88A(Fe) for bacteria
mimicking, MIL-100 (Fe) nanoparticles were designed to have immunomodulatory
property by functionalized with the immunomodulatory ligand curdlan. Curdlan coated
MIL-100(Fe) was prepared by nanoprecipitation method. The difference in surface
charge, intracellular stability, and thermal property confirms the coat of curdlan on MIL100(Fe). Overall, MOFs are promising candidates for the development of biomimetic
particles as HDT to target infected cells. M.tb-mimetic MIL-88A(Fe) particles and
immunomodulator MIL-100(Fe) may potentially enhance host cell response to an M.tb
infection by encapsulated HDT drugs or the carriers themselves.

1
Chapter 1 Introduction
1.1 Tuberculosis
1.1.1 TB disease burden
Tuberculosis (TB) is an old disease that has affected humans for more than a millennium.
On March 24, 1882, Dr. Robert Koch presented his finding to the Berlin Physiological
Society that TB was caused by a single infectious agent, Mycobacterium tuberculosis
(M.tb)[1]. In 2020, TB is the 13th leading cause of death and the number two infectious
disease killer after COVID-19 worldwide. From the Global 2021 TB report[2], 10.0
million people fell ill with TB. There were 1.5 million people who died from the disease
and an additional 214,000 deaths among HIV-infected people. Currently, it is estimated
that a quarter of the world population (2 billion) is infected with M.tb. Of those infected,
5-15% of those infected people will develop active TB and exhibit symptoms of the
disease. Most people who developed TB in 2019 were in South-East Asia (44%), Africa
(25%), and the Western Pacific (18%). However, two-thirds of the total TB cases in 2019
were in the following eight countries: India, Indonesia, China, Philippines, Pakistan,
Nigeria, Bangladesh, and South Africa. Globally, the TB incidence rate and the number
of TB deaths are falling but fail to achieve the 2020 milestone of 20% reduction in TB
incidences.
1.1.2 Pathogenesis of infection
This is an overview that will be expanded in later sections.
TB is an airborne infectious disease that begins when an individual inhales M.tb aerosols.
M.tb is rod-shaped bacilli, of 0.2-0.5 µm in diameter and 2-4 µm in length[3]. Bacilli
travel down the airways into the alveoli of the lungs, where they start to multiply. Most of
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these bacilli are recognized and engulfed by alveolar macrophages at the early stage of
infection, where they will be killed or inhibited. However, some bacilli can survive and
replicate intracellularly. The bacteria usually attack the lungs, but, in some cases, a small
number of bacilli may spread through the lymphatic channels or the bloodstream to other
parts of the body, such as lymph nodes, central nervous system, kidneys, and bone[4].
This dissemination process primes the immune system for developing an effective cellmediated immune response to control the further multiplication of the bacteria. Infected
alveolar macrophages release various cytokines to recruit the different populations of
cells, including additional macrophages, dendritic cells, and lymphocytes to the site of
infection. Those cells form the beginning of a granuloma, as the immune system attempts
to ward off the bacteria. Granuloma is the pathologic hallmark of tuberculosis[5]. Inside
the granuloma, most bacilli are killed, and the disease is under control. However, the host
cannot entirely eradicate bacilli, M.tb has evolved strategies to persist in the granuloma.
Those bacilli reprogram their metabolism to a dormant state and survive for decades
(Latent TB). For those individuals whose immune system is compromised (HIV
infection), the granuloma tends to liquefy and cavitate. Other medical (e.g., malnutrition,
aging, diabetes, cancer) or genetic factors can also trigger the reactivation of bacteria.
The destruction of granuloma leads to releasing many M.tb into the lungs and thence into
the environment (Active TB). When people who have active TB cough, sneeze or talk,
the highly transmissible infectious droplet of bacilli will release into the air, and people
around may inhale them and become infected.
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1.1.3 Pulmonary TB
1.1.3.1 Latent TB
Latent TB infection (LTBI) is a state of persistent immune response to stimulation by
M.tb. People with LTBI have M.tb, which is non-replicating in their bodies, and does not
clinically manifest active TB disease. LTBI infected individuals cannot spread the
infection to other people. The process of LTBI begins when extracellular M.tb is
internalized by alveolar macrophages and presented to other monocytes, which triggers
the immune response to form a granuloma. At this point, LTBI has been established.
Bacilli can priest within the granuloma for a long time. There are no immediate
symptoms, but LTBI may be detected by the tuberculin skin test (TST) or interferongamma release assay (IGRA)[6]. In most cases, people who have latent TB never develop
active TB disease. However, about 5-10% of people with TB infection due to a weakened
immune system, will experience reactivation of LTBI and progress to active disease.
1.1.3.2 Active TB
In some people, if their immune system cannot keep the M. tb under control, the tubercle
bacilli multiply rapidly. Persons who have TB disease are usually contagious and may
spread the bacteria to other people. The general symptoms of active TB include coughing
for three weeks or longer, coughing up blood, chest pain, trouble breathing, weight loss,
and/ or fever. TST and IGRA can only indicate that a person has been infected with M.tb.
It does not distinguish if the person has LTBI or active TB. Chest X-ray and sputum
culture tests are needed to confirm the TB disease.
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1.1.4 Drug-resistant TB
1.1.4.1Drug resistant TB burden
The emergence of Drug-resistant TB is of great concern, as the treatment requires more
toxic and expensive drugs than first-line drugs. Worldwide, drug-susceptible TB
treatment success rates are at least 85%, while the latest report shows the success rate for
multi-drug resistant TB treatment is only 57%[2]. WHO reported an estimated 182,000
deaths in 2019[2]. In general, treatment for patients with drug-resistant TB is longer and
less effective. In addition, detection is also a significant obstacle to effective TB
treatment and prevention. In 2019, there were an estimated 465,000 cases of drugresistant TB[2]. India, China, and the Russian Federation accounted for nearly 50% of
global resistant cases[2]. However, only 206,030 people were detected among those
people, and 177,099 people received treatment[2].
1.1.4.2 Drug-resistant TB types
Drug-resistant TB can develop in two different ways. Primary resistance occurs in
persons who are initially infected with resistant strains. Secondary resistance (or acquired
resistance) happens during TB treatment. Drug-resistant TB occurs when current anti-TB
drugs used to treat the disease can no longer kill the M.tb. Mostly because patients did not
take medication appropriately, or they were treated with an inadequate regimen.
Drug-resistant TB can be either mono-resistance, resistance to one first-line anti-TB drug
only, or poly-resistance, resistant to more than one first-line anti-TB drug. Multidrugresistant TB (MDR-TB) is defined as resistance to at least both isoniazid (INH) and
rifampicin (RIF), the two most powerful first-line anti-TB drugs. Extensively drugresistant TB(XDR-TB) is a rare type of MDR-TB defined as resistant to any second-line
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anti-TB drugs: fluoroquinolone and at least one of three injectable drugs (i.e., amikacin,
kanamycin, or capreomycin), in addition to INH and RIF. Rifampicin resistance TB(RRTB) is a form of TB that a strain is resistant to rifampicin with or without resistance to
other anti-TB drugs.
1.1.5 Current anti-TB treatment
Treatment for drug-susceptible TB has an intensive phase of 2 months, including
isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA),
followed by a continuation phase of either 4 or 7 months with INH and RIF. INH is one
of the most widely used and effective anti-TB drugs for TB treatment since its activity
was discovered in 1952[7]. INH is highly active against growing bacilli with a MIC in
the range of 0.01 to 0.25 µg∙mL-1 but not active against resting bacteria[8]. Despite its
simple structure, the mechanism of action is very complex as it interferes with many
metabolic pathways. Unlike INH, RIF is bactericidal against both actively growing and
non-growing bacilli. It binds to the β-subunit of DNA-dependent RNA polymerase(rpoB)
of M.tb, resulting in inhibition of transcription activity of bacilli[9]. EMB is a synthetic
compound with a similar structure to D-arabinose. As an arabinose memetic, EMB
competitively interferes with the arabinosyltransferases, inhibiting the biosynthesis of the
cell wall component, arabinogalactan(AG)[10]. PZA is a prodrug that needs to be
converted to its active form, pyrazinoic acid (POC)[11]. PZA plays a crucial role in
shortening the course as it kills non-replicating bacilli in acidic environments.
Streptomycin (SM), an aminocyclitol glycoside antibiotic, was the first antibiotic to treat
TB[12]. SM binds to the 16S rRNA, causing misreading of the mRNA and inhibition of
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protein synthesis[12]. As a single-drug therapy, SM exhibited a high level of resistance
and severe side effects; therefore, SM usage has considerably declined.
Fluoroquinolones (FQs) which target DNA gyrase, exhibit a broad-spectrum antibacterial
activity[13]. FQs include ciprofloxacin, ofloxacin, levofloxacin, and moxifloxacin.
Currently, FQs are primarily used in the treatment of MDR-TB or as second-line drugs
for patients who cannot tolerate the first-line medications.
Injectable anti-TB drugs include two different antibiotic families: aminoglycosides and
cyclic polypeptide. They are both critical for the treatment of MDR-TB. Amikacin (AMK)
and kanamycin (KAN) are aminoglycosides. Capreomycin (CAP) belongs to the cyclic
polypeptide. They exert their action by binding to the ribosomes and inhibiting protein
synthesis.
Bedaquiline (BDQ) and delamanid (DLM), which the FDA approved in 2012 and 2014,
respectively, are used to treat latent TB and MDR- /XDR-TB[14, 15]. BDQ interferes
with bacterial energy metabolism by inhibiting mycobacterial ATP synthase[16]. DLM is
a prodrug activated by the mycobacterial F420 coenzyme system to form a reactive
intermediate metabolite that inhibits mycolic acid synthesis[17]. In 2019, the FDA
approved pretomanid (PTM), a compound developed by the nonprofit TB Alliance,
combined with BDQ and linezolid (LZD) to treat extensively drug-resistant pulmonary
TB[18]. PTM is also a prodrug activated by a nitro-reductase enzyme. In addition, it is
active against replicating and non-replicating mycobacteria via the inhibition of mycolic
acid synthesis and the production of nitric oxide, respectively[19].
Figure 1.1 gives an overview of currently used anti-TB drugs and target of action.
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Figure 1.1 Target of action of currently used anti-TB drugs.
1.1.6 Challenges of TB treatment
The main challenge with current drugs is the lengthy and complex treatment regimens,
which highly affect patient compliance. Currently, the WHO recommends a Directly
Observed Therapy Short-Course (DOTS) program for TB management; this program
includes direct observation of the consumption of every dose of TB drugs by trained
personnel. Cure rates are very high (85% in 2018) for drug-sensitive strains when patients
adhered to recommended protocols. However, it is difficult to prescribe and follow these
protocols in many high TB burden countries, predominantly low-income countries.
Incompletion of treatment plays a significant role in the emergence of drug-resistant TB.
The treatment of MDR TB must rely on second-line drugs, which are less effective, more
toxic, and more expensive than first-line drugs. The high prevalence of co-infection with
M. tb and HIV creates additional therapeutic challenges due to drug-drug interactions
between anti-tuberculosis and antiretroviral drugs and overlapping toxicities. Therefore,
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new anti-TB agents or new effective and affordable therapies are highly needed to
combat TB.
1.2 Immunology of TB infection
1.2.1 Physical barrier
The mucous membrane of the respiratory tract, which is in contact with the external
environment, acts as a physical barrier to prevent microbes from reaching the alveoli. The
mucociliary escalator is the most critical barrier, consisting of two parts, ciliated
epithelium and mucous film[20]. The lung epithelial cells are ciliated, covered by a thin
layer of fluid, the periciliary sol layer. Those ciliated cells are tiny muscular and hair-like
projections with a continual beating motion that can beat freely in the sol layer[21].
Above that is the mucus gel layer produced by the goblet. This layer is very viscous and
sticky, which helps protect the underlying cells and assist in trapping any inhaled
particulates or pathogens[22]. The cilia can contact the mucous layer during the forward
stroke, propelling the mucus towards the mouth and coughing out mucus and trapped
particulates.
Only small particles, less than 2-5 µm, which the mucociliary escalator fails to remove,
enter the deep lung, alveoli, which are not protected by mucus and cilia. M.tb can
successfully escape the upper airway ciliary beat, the cough reflex, and mucociliary
escalator and traverse the trachea and the bronchi to reach the alveoli. There are three
types of alveolar cells, Type I pneumocytes, Type II pneumocytes, and alveolar
macrophages (AMs). Type I cells are thin and flat (squamous), covering 95% of the
alveolar surface. They are essential for gas exchange and maintenance of barrier function
of lungs[23]. Type II cells are cuboidal and round and much smaller than Type I cells.
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Although they are the most numerous cells in the alveoli, Type II only make up 5% of the
alveolar surface. The major functions of Type II cells are to secrete pulmonary
surfactants and repair the alveolar epithelium when cells are damaged[24]. AM is the
third cell type which is located on the luminal surface of alveoli. They are the primary
lung resident phagocytes involved in the initial immune response. Although AMs rapidly
engulf deposited M. tb, they are less able to control and kill all of the bacilli. Ultimately,
AMs become major niches for M.tb and even facilitate the migration of bacteria to
lymph nodes which later causes systemic dissemination[25, 26].
1.2.2 Innate and adaptive immunity
The immune responses to M. tb are composed of innate immune responses and adaptive
responses. Adaptive immunity in TB infection generally delays[27]; therefore, innate
immunity, which is the first line of defense, plays a significant role against M.tb at the
early time point. Innate immune cells include macrophages, dendritic cells, neutrophils,
and natural killer cells. Other cells, such as airway epithelial cells (AECs) and mast that
have also contributed to the early immune response against M.tb, are also considered
innate immune cells[28]. These immune cells express various pattern recognition
receptors (PRRs), which recognize the pathogen-associated molecular patterns (PAMPs)
on the surface of M.tb. (Described in Section 1.3). The pathogen recognition by innate
cells triggers a cascade of cellular events, such as phagocytosis, autophagy, and
inflammatory cytokine and chemokine production, to control and remove bacteria.
Infected DCs migrate to lymph nodes where T-cells undergo activation and expansion for
the M.tb antigens[26]. Two major mechanisms utilized by T-cells against M.tb are
cytotoxicity and cytokine production. Both CD4+ and CD8+ T-cells produce interferon-
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gamma (IFN-γ), which is critical for infection control[29, 30]. Other cytokines, such as
IL-6, IL-1, and TNF-α, are also involved against intracellular M.tb[31]. Tregs are found
to accumulate at sites of infection in human TB[32]. Tregs can exert negative effects,
such as suppressing CD4+ T cell activity and deactivating APCs(Antigen-presenting
cells)[33].
1.2.3 Phagosome maturation
M.tb enters macrophages by phagocytosis, during which phagosomes are formed by the
fusion of the cell membrane around engulfed M.tb. To kill the bacteria, phagosomes need
to go through maturation, including phagosome acidification and lysosome fusion. In this
process, nascent phagosomes gradually become more acidic from pH 6.5 to pH 4.5 and
more bactericidal by fusing with early endosomes, late endosomes, and lysosomes[34].
After fusion with lysosomes, phagosomes are referred to as phagolysosomes.
Phagolysosomes contain hydrolytic enzymes and free radicals, which are essential in
bacterial killing. In addition, macrophages recruit vacuolar proton pumps (v-ATPase) that
actively transfer H+ across membranes to acidify the compartment and denature bacterial
proteins in low pH.
However, M.tb can inhibit phagosome-lysosome fusion, restricting the compartment pH
from 6.2 to 6.4 and blocking enzyme activities[35, 36]. Therefore M. tb can survive
within the host and evade immune detection. It is found that secreted M.tb protein
tyrosine phosphatase (PtpA), essential for M.tb pathogenicity, binds to subunit H of the
macrophage v-ATPase complex, leading to blocking v-ATPase trafficking[35]. Therefore,
the level of v-ATPase on the mycobacterial phagosome membrane decreases. Another
M.tb secreted acid phosphatase, SapM, hydrolyzes phosphatidylinositol 3- phosphate
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(PI3P), which plays a vital role in the biogenesis of phagosomal membrane, thereby
preventing phagolysosome formation[37]. Nitric oxide (NO) is a critical antimycobacterial molecule that is generated by inducible nitric oxide synthase (iNOS) in
infected macrophages[38]. A study shows that M.tb can inhibit iNOS recruitment to
phagosomes during the infection[39]. Inhibition of phagosome maturation also further
affects macrophage antigen production and presentation.
1.2.4 Autophagy
Autophagy is an intracellular homeostatic process that mediates the degradation of
cytoplasmic components, including organelles and pathogens. Autophagy as an immune
mechanism acts as a cell-autonomous defense protecting the host against intracellular
M.tb. Bacteria are sequestered into a double-membrane vacuole, so-called
autophagosomes, and delivered to the lysosome for degradation, leading to antigen
presentation and T-cell activation. In addition to autophagosome formation, autophagytargeting molecule p62, an adaptor protein, is critical for M. tb killing activity. The p62
delivers specific cytosolic components to autolysosomes, in which those components are
processed into mycobactericidal products[40]. Stimulation of autophagy also overcomes
M.tb phagosomes maturation arrest[41, 42]. The human immunity-related guanosine
triphosphatases (IRGM) are involved in the autophagy-mediated clearance of M.tb by
interacting with mitochondrial lipid cardiolipin to promotes mitochondrial fission[43].
M.tb has developed several strategies to counteract autophagic defense. M.tb enhanced
intracellular survival (EIS) protein plays essential roles in inhibition of macrophage
autophagy, inflammatory responses, and cell death[44, 45]. The early secretory antigenic
target 6 (ESAT-6) secretion system-1 (ESX-1) of M. tb has been reported to be involved
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in inhibiting autophagy[46, 47]. M.tb lipoproteins, LprE, promote intracellular bacterial
survival by inhibiting cytokines, phagolysosome fusion, and autophagy[48].
1.2.5 Inflammation
Inflammation is regulated by both the host and M. tb during different stages of infection.
Infected AMs invade the low epithelial layer, accompanied by an intense local
inflammatory response, such as recruitment of immune cells and induction of proinflammatory cytokines. The interaction of M.tb with AEC and Type II alveolar cells
induces the secretion of tumor necrosis factor-alpha(TNF-α) and (IFN)-γ[49, 50]. M.tb
infection of macrophages also stimulates the production of IL-1β, which is another
critical pro-inflammatory cytokine for host defense[51]. However, M. tb has developed
various mechanisms to evade the host response and bypass the pro-inflammatory
response, leading to survival and replication inside AMs. Anti-inflammatory cytokines,
such as IL-10 and transforming growth factor-beta (TGF-β), are induced by M.tb-infected
AMs, which counteract pro-inflammatory molecules and reduce T cell activation[52].
These pro-inflammatory and anti-inflammatory cytokines stabilize the reciprocation
between bacterial clearance and proliferation.
1.2.6 Granuloma formation
The local inflammatory response results in the recruitment of macrophages, monocytes,
and other inflammatory cells to the site of infection, but those cannot effectively kill the
bacteria. Antigen-presenting dendritic cells (DCs) travel to lymph nodes where T
lymphocytes are activated and recruited. A mass migration of immune cells and secreted
cytokines and chemokines result in forming a specialized structure called granuloma
around the primary site of infection. In the granuloma structure(Fig 1.2), infected
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macrophages, epithelioid cells (differentiated macrophages), and multinucleated giant in
the middle are surrounded by T-cells[53, 54]. The necrotic zone develops in the inner
core of the granuloma while the outer surface is covered by fibrous tissue and
vasculature[55, 56]. The granuloma creates an immunological microenvironment in
which bacilli can survive and grow but contains the spread of M.tb. Bacteria may persist
and remain dormant for a lifetime without developing active disease. However, excessive
bacterial growth may lead to necrosis and apoptosis of infected macrophages, releasing
the bacteria and promoting inflammation and tissue damage.

Figure 1.2 Schematic of the cellular constituents of a TB granuloma. Adapted from
reference[57].
1.3 Macrophage interaction with M. tb
AMs reside beneath the surfactant layer of the alveolar lumen, which are the first to
phagocytize M. tb when they settle in the alveolus. In addition, a few AMs are embedded
in the connective tissue between alveoli. M.tb expresses antigenic molecules called
pathogen-associated molecular patterns, recognized by pattern recognition receptors on
phagocytic cells, such as macrophages and dendritic cells. M.tb gains entrance into cells
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through receptor-mediated phagocytosis. Activation of PRRs at a different stage of
infection initiates signaling cascades in response to the recognition, engulfment, and
destruction of M.tb. Macrophages have been classified into two major groups, the proinflammatory (classically activated) M1 type and the anti-inflammatory (alternatively
activated) M2 type. Macrophage-induced pro- or anti-inflammatory response highly
depends on different PRRs.
1.3.1 Mycobacterial cell envelope
M.tb has a unique cell envelope structure which plays an essential role in intrinsic
antibiotic resistance and virulence. The M. tb cell envelope consists of a typical plasma
membrane, a complex cell wall, and an outer capsule (Fig 1.3). The main structural
components of the cell wall are the peptidoglycan (PG) layer, the arabinogalactan (AG)
polysaccharide, and the mycolic acids (MA) layer. Between the plasma membrane and
PG, there is the gelatinous material called periplasm. Lying outside the plasma membrane,
PG is covalently linked to AG via a phosphodiester bond. Both gram-negative and grampositive bacteria have PG, composed of repeating units of N-acetylglucosamine (GlcNAc)
and N-acetylmuramic acid (MurNAc). However, mycobacterial PG contains oxidized
MurNAc, N-glycolylmuramic acid (MurNGlyc). It appears that this modification
increases the resistance of mycobacterial PG to lysozyme[58]. The highly branched AG
layer is composed of D-arabinofuranoses and D-galactofuranoses. The galactan domain
of AG connects to selected MurNGlyc. The arabinan unit of AG serves as an attachment
site for those α-branched and β-hydroxylated long-chain(C60-C90) fatty acids, mycolic
acids. The acid-fastness of the genus Mycobacterium is directly related to a high amount
of MA, approximately 60% of the weight of the cell wall. Several extractable glycolipids
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intercalate into the MA layer to form a “pseudo” lipid bilayer, such as trehalose monomycolates (TMMs), trehalose dimycolates (TDMs, cord factor), phenolic glycolipids
(PGLs), phosphatidylinositol mannosides (PIMs), phosphatidylethanolamine (PE),
triacylglycerols (TAGs), and lipoarabinomannan (LAM). The outermost capsule-like
layer of slow-growing mycobacterial species is rich in polysaccharides, such as α 1-4
glucan, arabinomannan, and mannan, whereas the rapid-growing species are abundant for
proteins[59].
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Figure 1.3 Schematic of the mycobacterial cell envelope. GL, granular layer; MmpL,
mycobacterial membrane protein large; PL, phospholipids. Adapted from reference[60].
1.3.2 Macrophage recognition of M. tb
1.3.2.1Toll-like receptors
Toll-like receptors (TLRs) are a family of single-pass membrane-spanning receptors
which play an essential role in both innate immune responses and initiation of adaptive
immunity to M.tb infection. Depending on the type of recruited adaptor proteins, TLRligand binding signaling can be mainly divided into MyD88 dependent pathway and
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TRIF dependent pathway, which induce the pro-inflammatory cytokines (IL-1β, TNF-α,
IL-6) and type I IFNs (IFNα), respectively[61].
Among the ten members (TLR1-TLR-10) that have been identified in humans, TLR2,
TLR4(extracellular receptors), and TLR9, TLR8 (intracellular receptors) are known to be
involved in recognition of M.tb. TLR2 can bind to various mycobacterial cell wall
components, such as lipoarabinomannan (LAM)[62, 63], lipomannan (LM)[64, 65],
lipoprotein (LP)[62, 66-68], and phosphatidyl-myo-inositol mannoside (PIM)[62]. TLR2
can form a heterodimer with either TLR1 or TLR6, interacting with di- and tri-acylated
LP, respectively. TLR4 binds to different components of M.tb, including 65 heat shock
protein (HSP65)[69], 50S ribosomal protein (50S RP)[70], and tri-and tetra-acylated LM.
TLR9 localized in the endosomes and phagolysosomes can recognize mycobacterial
DNA with unmethylated CpG (cytosine-phosphate-guanine) dideoxynucleotides[71].
Keegan et al. reported that mycobacterial tRNA triggered a distinct innate immune
response via TLR8[72].
1.3.2.2 C-type lectin receptors
C-type lectin receptors (CLR) are a family of transmembrane calcium-dependent
receptors that binds a range of carbohydrate-rich molecules, including trehalose 6,6’
dimycolate (TDM), PIMs, LAM, and LM. CLRs that interact with M.tb include mannose
receptor (MR), Mincle, Dectin-1, Dectin-2, and DC-SIGN.
MR is a type I transmembrane CLR expressed on the surface of alveolar macrophages,
M2 macrophages, and dendritic cells. The binding of MR to mannose residues of
lipoarabinomannan (ManLAM) medicates phagocytosis of M.tb by macrophages[73, 74].
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Mincle, a type II transmembrane CLR expressed on the surface of macrophages, has been
shown to recognize TDM[75, 76]. TDM activates macrophages to produce nitric oxide
and pro-inflammatory cytokines contributing to antibacterial function and granuloma
formation, respectively[75, 77].
Dectin-1 and Dectin-2 are type II transmembrane CLR. Dectin-1 has been extensively
characterized as a major receptor for β -1,3-glucan. In addition, many studies have
associated Dectin-1 with mycobacteria’s recognition and innate immune response [78-80],
although its mycobacterial ligand remains unknown. Dectin-2 specifically recognizes
ManLAM, resulting in the production of inflammatory cytokines[81, 82].
Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DCSIGN) is a type II transmembrane receptor mainly expressed on DCs and plays a role in
mycobacterial-induced immune suppression. In addition, DC-SIGN recognizes ManLAN
and LM and produces anti-inflammatory cytokine IL-10[83, 84].
1.3.2.3 Complement receptors
Complement receptors (CRs) are membrane proteins expressed on the surface of
phagocytes. M.tb can activate the alternative pathway of the complement system,
resulting in opsonization with C3b and C3bi enhancing phagocytosis. CR1, CR3, and
CR4 are involved in the phagocytosis of M.tb [82, 83]. It is reported that CR4 is the most
abundant C3 receptor on human alveolar macrophages compared to CR1 or CR3[85]. In
addition, a prior study demonstrated non-opsonic M.tb could directly bind to monocytederived macrophages via CR4. This indicates that CR4 plays a significant role in M.tb
and macrophage interaction at an early stage of infection when opsonins are unavailable
[86].
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1.3.2.4 NOD-Like receptors
The nucleotide oligomerization domain (NOD) like receptors (NLRs) are intracellular
proteins containing leucine-rich repeats. NLRs are responsible for the recognition of the
PAMPs of a pathogen, bacterial peptidoglycan-derives. NOD2 is a receptor for muramyl
dipeptide (MDP) in most bacteria. However, M.tb produces the modified form of MDP,
N-glycolyl MDP[87]. N-glycolyl MDP is also more potent for activation of NOD2, which
leads to both innate and adaptive immunity[88]. NOD2-deficient mice showed impaired
production of cytokines upon infection with M.tb[89].
1.3.2.5 Other receptors
Scavenger receptors (SRs) and Fc receptors are also involved in M.tb recognition and
immunity responses but play a less important role than other receptors discussed above.
SRs are expressed on the surface of macrophages and bind to numerous ligands,
including host-modified ligands and bacterial cell wall components. It is reported that
Class A SR, MARCO, was involved in recognizing TDM[90]. SR-B1 has been shown to
mediate the binding of M.tb in RAW264.7 macrophages[91]. Fc receptors are found on
the surface of hematopoietic cells and are involved in antigen recognition. Fcγ receptors
bind to IgG-opsonized M.tb and mediate cellular response during M.tb infection[92].
1.3.2.6 Others
Pulmonary surfactant, a complex of lipids and proteins, forms a thin layer at the alveolar
surface. It is made up about 70%-80% phospholipids, mainly dipalmitoylphosphatidylcholine (DPPC), 10% surfactant protein A, B,C and D (SP-A,B,C,D) and 10%
neutral lipids, mainly cholesterol[93]. Pulmonary surfactant also plays an important role
in M.tb-AM interaction. SP-A has been found to enhance AM phagocytosis via up-
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regulation of mannose receptor activity[94, 95]. In contrast, by binding to mannosylated
lipoarabinomannan (ManLAM), SP-D decreases phagocytosis of M.tb while increases
fusion of M.tb containing phagosomes with lysosomes[96, 97]. Cholesterol may also play
a part in host-pathogen interaction. It has been found to accumulate around the site of
M.tb entry in macrophages[98].
1.4 Host-directed therapy (HDT)
Although TB is treatable by antibiotic therapy, it is often associated with prolonged
duration, poor patient compliance, and, most importantly, the development of drug
resistance M.tb strains. In addition, the treatment of MDR- and XDR- TB is expensive,
less effective, and more toxic. Therefore, recent attention has focused on host-directed
therapy (HDT), which aims to restore or enhance the host immune response to M.tb
infection and minimize inflammatory tissue damage. HDT includes, but is not limited to,
agents that (a) change the integrity of granuloma;(b) induce autophagy; (c) modulate proand anti-inflammatory responses; and/or (d) regulate cell-mediated immune responses.
HDT could also act as adjuvant therapy for standard TB treatment to shorten the duration
of the regimen and improve treatment outcomes.
1.4.1 Granuloma disruption
One of the hallmarks of TB is the extensive formation of granuloma, which can restrict
the access of drugs to the center of granuloma. Granuloma can be a niche where bacilli
persist in the latent form until they have a chance to reactivate. On the other hand,
disruption of granuloma may cause multiplication and dissemination of extracellular
bacteria. TNF-α is an inflammatory cytokine involved in host immunity against M.tb
infection. It is also essential in the formation and function of granuloma[99]. When TNF-
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α is blocked, it leads to granuloma disintegration. However, it may also cause an
unregulated inflammatory response. Therefore, it is important to understand the dose-or
time-dependent cytokine response of anti-TNF- α therapy. A recent study shows antiTNF- α antibody (Enbrel) combined with chemotherapy enhanced M.tb clearance and
reduced lung pathology[100]. A major similarity between cancer and granuloma is
central hypoxia and necrosis due to abnormal angiogenesis. Therefore, targeting the
granuloma microenvironment is a promising therapeutic strategy. Vascular endothelial
growth factor (VEGF) and angiopoietins (Angs) have been shown to increase in active
TB patients compared to healthy people[101, 102]. Bevacizumab (anti-VEGF antibody)
has been shown to normalize vasculature and reduce hypoxia, facilitating small molecule
delivery in the rabbit TB granuloma model[56]. Pozopanib, a VEGF receptor inhibitor,
reduced infection burden and limited dissemination of bacteria in the zebrafish model by
inhibiting vascularization. This anti-angiogenic therapy also increased the efficacy of
anti-TB drugs, rifampicin, and metronidazole[103].
1.4.2 Autophagy treatment pathway
Autophagy is a lysosomal degradation of harmful cellular macromolecules and organelles.
Phagosomes containing M.tb can fuse with autophagosomes and lysosomes, resulting in
bacteria killing. Besides pathogen clearance, autophagy is also part of innate immunity,
which acts as a modulator of pro-inflammatory cytokine secretion and involves antigen
processing and presentation[104]. Autophagy can be regulated via mammalian target of
rapamycin (mTOR), AMPK-activated protein kinase pathway, vitamin D receptor
signaling, and stimulator of IFN genes (STING)-dependent pathway. Rapamycin is an
immunosuppressive drug used in organ transplantation. It is an inhibitor of the Ser/Thr
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protein kinase mTOR, a suppressor of autophagy induction. Rapamycin has been shown
to promote autophagy-mediated M.tb killing[105, 106]. Activated AMPK promotes
autophagy against M.tb by inhibiting mTOR in macrophages[107]. Metformin, an antidiabetic drug, can limit the intracellular growth of M.tb via the AMPK pathway[108].
Activation of vitamin D receptor (VDR) signaling by vitamin D induces the production
of various antimicrobial peptides, including cathelicidin and autophagy of M.tb infected
cells[109, 110]. STING, a transmembrane protein that can recognize extracellular
bacterial DNA, triggers ubiquitin-mediated selective autophagy, resulting in the delivery
of M.tb to autophagosomes[111].
1.4.3 Inflammatory response modulation
The balance between pro-and anti-inflammatory responses is crucial in the control of TB
infection. Excessive pro-inflammatory immune responses often lead to chronic
inflammation and irreversible lung damage, whereas anti-inflammatory responses cause
minor tissue damage but may lead to pathogen survival and proliferation.
Corticosteroids are a class of glucocorticoid receptor antagonists that can downregulate
the expression of pro-inflammatory cytokines[112, 113]. Although corticosteroid therapy
has not been shown to improve the pulmonary TB regimen with anti-TB drugs
significantly, it is recommended in TB meningitis as an adjuvant treatment[114, 115].
Matrix metalloproteinases (MMPs) contribute to tissue damage and pulmonary cavitation
in TB patients by degrading the extracellular matrix and exacerbating the
inflammation[116]. Doxycycline, an MMP inhibitor, has decreased MMP activity and
suppressed M.tb growth in vitro and the guinea pig model[117]. Marimastat, a broadspectrum MMP inhibitor, decreased granuloma formation and M.tb growth in the human
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lung tissue model[118]. Poly (ADP-ribose) Polymerase-1 (PARP-1), mainly known for
its role in DNA repair, is also a key regulator of inflammatory cytokines, TNF-α, NF-κB,
and MMP[119-121]. Inhibition of PARP-1 has been shown to reduce inflammatory
conditions[122]. Therefore, PARP inhibitors might be used as HDTs to improve TB
therapy by reducing inflammation and tissue damage.
Aspirin, an anti-inflammatory drug, has been reported to enhance pyrazinamide treatment
in the TB mouse model[123]. One study shows that aspirin improved the clinical efficacy
of standard anti-TB regimens in patients with pulmonary TB and type 2 diabetes
mellitus[124]. In addition, ibuprofen without other anti-TB treatments has shown
significant decreases in M.tb load and lung lesions and improved survival in the mouse
model[125].
1.4.4 Cell-mediated immunity
It is reported that the level of myeloid-derived suppressor cells (MDSCs) increased after
M.tb infection, resulting in suppression of T-cell function[126]. Tasquinimod (TSQ) is a
novel anti-cancer drug that impairs both infiltration and function of MDSCs in the tumor
environment[127]. Gupta et al. found that in the TB mouse model, TSQ treatment
decreased MDSC frequency during TB infection and successfully reduced M.tb burden in
infected lung and spleen[128]. CD4+CD25+ regulatory T-cells (Tregs) have suppressive
properties by down-regulating effectors functions of CD4+ and CD8+ T-cells. It is
reported that Tregs may contribute to the suppression of Th1-type immune responses[32].
Denileukin diftitox (DD), a diptheria toxin-related IL-2 fusion protein toxin used for
refractory cutaneous T-cell lymphoma, has been shown to deplete Tregs[129]. DD
monotherapy significantly decreased MDSCs and Tregs in the lung and spleen, reducing
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M.tb replication in the mouse model[130]. When taken with standard TB treatment, DD
significantly improved the M.tb clearance[130]. IL-10 is a key anti-inflammatory
cytokine that suppresses T-cell function and promotes M.tb progression[131].
Macrophages transformed from M1 to M2 during M.tb infection[132]. It has been
reported that the increased expression of IL-10 was consistent with the increase of M2
macrophages, and a large amount of M2 macrophages were found in granulomas[132,
133]. Beamer et al.reported that anti-IL-10 receptor antibody treatment stabilized the
lung M.tb load, improved survival, and enhanced T cell responses in the CBA/J mouse
model[131].
1.5 Metal-organic frameworks (MOFs)
Metal-organic frameworks (MOFs) are a novel class of hybrid crystalline porous
materials that consist of a regular array of single metal ions or clusters of ions
coordinated to organic “linker” molecules. Different metal centers and linkers are applied
to produce MOFs with suitable and desirable characteristics for various applications.
MOFs have been used in multiple fields, such as catalysis, sensors, gas storage and
separation, toxin removal, batteries, and supercapacitors.[134].
1.5.1 Drug delivery system
Many remarkable properties enable the potential of MOFs as drug delivery systems. The
large surface area, high porosity, and tunable pore size of MOFs are beneficial to drug
encapsulation. Pore size and porosity highly depend on the dimensions of the network by
metal clusters and the length of linkers. The versatility of construction and chemical
compositions may contribute to good water solubility, biodegradability, biocompatibility,
and flexibility. As for metals, Ca, Cu, Mn, Mg, Zn, and Fe are generally used for drug
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carriers as they are biocompatible and exist in an appreciable amount in the body[135].
Organic linkers are either exogenous or endogenous compounds. The most used
exogenous linkers are polycarboxylates, imidazolates, pyridyl, and amines. Endogenous
linkers could be ideal for drug delivery applications as the organic linker might be reused
in the body, reducing the risk of toxicity. At least 28 different endogenous linkers were
previously reported, such as amino acid, cyclodextrin, and nucleobases[136]. The
stability of MOFs is another main topic for their use in drug delivery systems. The
degradation of MOFs facilitates the diffusion of drugs from the materials. However, the
appropriate stability of MOFs is required to prevent premature drug release. The stability
relies on chemical composition, crystallinity, and the biological environment.
Iron (III) carboxylate MOFs, MIL-100, and MIL-88A (MIL= Materials of Institute
Lavoisier) were used as delivery systems in this dissertation work. MIL-100 was built up
from a hydrophilic aromatic linker, trimesate, while MIL-88A was made from a
hydrophilic aliphatic linker, fumarate. They both have reasonable degradability and low
toxicity. The major degradation of MIL-100 and MIL-88A under physiological
conditions was found after seven days of incubation at 37 o C[137]. The toxicity of
degradation products is estimated by oral lethal dose 50 (LD50) (Fe=30g∙kg-1; trimesic
acid=8.4g∙kg-1; fumaric acid=10.7g∙kg-1)[135, 137]. Of note, iron fumarate, which has the
same chemical composition as MIL-88A(Fe), has been approved as an oral iron
supplement[138]. This indicates the body might clear MIL-88A(Fe) composition without
adverse effects. In vivo toxicity studies of MIL-100 and MIL-88A were performed
through intravenous administration in Wistar female rats[137]. There were no detrimental
effects of MOF on animal behavior, animal and organ weight evolution, and enzymatic
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activities. Another important feature of these iron carboxylate MOFs is the potential as
contrast agents. The efficiency of iron-based MOFs as MRI contrast agents is related to
their capacity to modify the relaxation time of the water protons. MIL-100 and MIL-88A
are constructed with large amounts of paramagnetic iron atoms and possess an
interconnected porous matrix filled with metal coordinated and free water molecules[137].
It has been reported that the iron-based MOFs show favorable relativities and imaging
properties[137, 139]. The MIL family is a very promising group of MOFs in drug
delivery. Besides the two advantages discussed above, high drug loading capacities, good
control release profiles, and the possibility for further functionalization have also been
widely reported.
1.5.2 MOFs as anti-TB drug delivery systems
Iron-based MOFs have been reported as anti-tuberculosis drug carriers. Wyszogrodzka et
al. reported using Fe-MIL-101-NH2 as an extended-release carrier for anti-TB drug
isoniazid and proved this iron-MOF can also serve as a MIR contrast agent [140]. Simon
et al. demonstrated that the MIL-100(Fe) drug delivery platform for isoniazid showed a
good controlled-release profile[141]. 3D printed mesoporous bioactive and iron-based
MOF scaffolds have been fabricated for anti-TB drug delivery[142]. The system exhibits
good biocompatibility and bioactivity with a sustained drug release behavior.
In addition to Fe-MOFs, Cui et al. developed ZnO nano-cages derived from zeolitic
imidazolate framework-8(ZIF-8), which showed inhibiting the growth of M.tb[143]. Luz
et al. developed copper-based MOF particles using pyrazinoic acid (prodrug for
pyrazinamide) as linkers via spray drying for multi-drug resistant TB with desirable
aerodynamic properties for pulmonary administration[144].
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1.6 Biomimetic drug delivery systems
1.6.1 Introduction
“Biomimetic” was coined by Otto Schmitt in 1957, who first explained this matter with
biophysics[145]. Expanding his expression leads to the following definition:
“Biomimetics is not so much a subject matter as it is a point of view. It is an approach to
problems of technology utilizing the theory and technology of the biological sciences”.
The natural world provides versatile sources of inspiration for designing biomimicking
drug delivery. Biomimetic particles usually exhibit functional merits similar to their
mimicked entities by two approaches: 1) the surface modification with lipids, saccharides,
and amino acids of biological entities; and 2) engineering the physicochemical properties,
like size, shape, and stiffness. Particles engineered with the existing cell membrane
components or specific biological entities can inherit the characteristics of source cells,
such as tumor targeting, prolonged circulation, and immune modulation. For example,
cell surface carbohydrates play an important role in cell recognition and immune
modulation. Ganbold et al. reported nanoparticles functionalized with mannose
efficiently delivery siRNA to primary mouse peritoneal macrophages by targeting
mannose receptors present on the surface of macrophages[146]. Polyanhydride
nanoparticles with galactose modified antigen-induced high avidity antibody response
and enhanced CD4+ T-cells proliferation[147]. Red blood cells (RBC) and platelet
membranes both express an immunosuppressive protein, CD47, which acts as a “ do not
eat me” marker to avoid uptake by macrophages[148]. Hu et al. developed PLGA
nanoparticles with RBC membrane, including the corresponding lipids and surface
proteins as a biomimetic delivery system. The biodistribution study shows high particle
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retention in the blood 72 h after injection in mice[148]. Platelet membrane coated
nanogel with TNF-related apoptosis-inducing ligand and doxorubicin exhibited high
accumulation in the tumor site resulting in promising antitumor efficacy in the mouse
breast cancer model[149].
In addition, the morphology of particles has also received increasing attention in drug
delivery. The particle shape influences the particle-cell interactions by either generating
varied angles or providing different curvatures. Rod-like or disc-like particles with a
higher aspect ratio within a specific range are reported to be uptake by cells more
efficiently than spherical-shaped ones[150]. Besides high uptake, rod-like particles also
showed prolonged circulation, preferential accumulation in a particular organ, and
different immune responses[151]. The shape of particles is shown to impact the intrinsic
physicochemical properties of drug carriers. For example, Reguera et al. described gold
and silver nanoparticles with anisotropic shapes, namely nanorods, nanotriangles,
nanocubes, and nanostars, exhibited different plasmonic properties, thereby potentially
influencing their therapeutic effects[152]. Stiffness also has an impact on cellular uptake
and circulation of particles. RBCs have superior mechanical flexibility than spherical
cells, allowing them to pass through gaps narrower than their diameter. This feature is
highly desirable for developing drug carriers with improved infiltration capability.
1.6.2 Types of biomimetic delivery systems
1.6.2.1 Virus mimetics
Viruses have an intrinsic ability to avoid immune system recognition and then deliver
their genes into the host for self-replication. Therefore, virus-based particulates are of
interest in drug delivery, especially gene delivery. Virus vectors, such as adenovirus,
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retroviruses, and lentiviruses, have been used to deliver specific genes of interest[153].
However, they are pathogenic and often associated with safety concerns. Virus-like
particles (VLPs) and virosomes have been developed, which have the advantages of
viruses while avoiding introduction of viral genetic materials. VLPs are self-assembled
particles of the virus-derived capsid or envelop proteins. Virosomes are bilayer
phospholipids sphere-shaped vesicles incorporated with the surface glycoproteins of
viruses. Virosomes were originally generated by liposomes and influenza virus subunits,
haemagglutinin (HA), and neuraminidase (NA)[154]. VLPs and virosomes have been
utilized in vaccines as they contain virus-specific antigens. For example, VLP HPV
vaccines approved by FDA for cervical cancer were self-assembled from L1 major outer
proteins of the virus[155]. Virosome-based vaccines, such as influenza virus (Inflexal® V)
and hepatitis A virus (Epaxal®), have been on the market for decades[156, 157]. In
addition to the substantial progress in vaccine development, VLPs and virosomes can
load diverse payloads, including chemotherapeutics, proteins/peptides, siRNA, nucleic
acid, antibodies.[158, 159]. Kaczmarczyk et al. demonstrated that VLPs could effectively
deliver several proteins to the cells, including GFP (Green fluorescent protein), Cre
recombinase, and human caspase 8. VLPs can be modified with specific ligands on the
surface to cause corresponding cellular responses[160]. Waelti et al. described
doxorubicin virosomal formulation, which conjugated Fab’ fragment of the monoclonal
antibody, showing the inhibition of tumor formation in the breast cancer mouse
model[161]. Inspired by the success of VLPs and virosomes for drug delivery, many
researchers have been trying to develop synthetic virus-mimicking particles by mimicing
either surface topology or function of the virus. Lee et al. described a pH-sensitive
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nanogel with folate ligands loaded with an anti-cancer drug; doxorubicin resembled
structural and functional virus features [162]. To mimic a capsid-like viral shell, one end
of polyethylene glycol (PEG) was connected to the core polymer and another end to
bovine serum albumin (BSA). PEG and BSA components may help to avoid immune
responses. Folate ligands known to be recognized by folate receptors highly expressed on
tumors may enhance the anti-cancer activity due to active targeting. This nanogel was
pH-sensitive; when pH was cycled between 7.4(cytosolic pH) to 6.4(early endosomal pH),
the particles reversibly swelled and shrank, closely associated with the drug release. In
addition, due to proton buffering effect of poly(L-histidine-co-phenylalanine), endosome
membranes were disrupted to facilitate nanogel transfer from the endosomes to the
cytosol. The virus-mimicking nanogels were found to migrate to the neighboring cells
and repeated the same cycle. Therefore, the infection cycle of viruses was essentially
replicated.
1.6.2.2 Bacteria mimetics
Like virus-based carriers, bacteria are also used as vectors for gene delivery systems. For
example, attenuated Salmonella typhi was used as a multi-drug resistance gene (MDR1)
siRNA delivery vector in a human tongue squamous cell cancer mouse model[163].
E.coli was engineered to produce a short hairpin RNA (shRNA) against human colon
cancer[164]. The use of non-genetic engineering of bacteria has also been introduced.
Akin et al. described a bacteria-mediated delivery system, microbots, using Listeria
monocytogenes bacteria to attach streptavidin-coated nanoparticles, which contain
therapeutic plasmid DNAs[165]. Another type of bacteria-based delivery system is
bacterial ghosts which are non-denatured cell envelopes of Gram-negative bacteria
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devoid of the cytoplasmic content[166]. Bacterial ghosts from Mannheimia haemolytica
were used to deliver doxorubicin (DOX), which exhibited more potent antiproliferative
activities on Caco-2 cells than free DOX[167]. Escherichia coli ghosts loaded with
plasmid DNA efficiently targeted murine macrophages and mediated gene transfer[168].
Gram-positive Enhancer Matrix (GEM) particles made from Lactococcus lactis bacteria
loaded with antigens containing a cell-wall binding domain have been used as vaccine
delivery[169, 170]. Recently, the design of bacteria-like particles containing the
components present in pathogens to promote cellular immune responses has gained much
attention, particularly in vaccine development. Those particles are usually designed to
trigger the activation of pattern recognition receptors. Seifert et al. described artificial
bacterial biomimetic PLGA nanoparticles encapsulating with unmethylated CpG-rich
oligodeoxynucleotides (CpG) and displaying monophosphoryl lipid A (MPLA) as a
vaccine platform[171]. MPLA and CpG are bacterial PAMPs recognized by TLRs to
initiate immune responses against pathogens. The particles loaded with model antigen
Ovalbumin OVA) exhibited enhanced TH1 immune responses and antibody-mediated
responses.
1.6.2.3 Cell mimetics
Natural cells, such as RBCs, macrophages, stem cells, have been explored as drug
carriers for an extended period[172-174]. RBCs have been one of the most widely used
cells to encapsulate therapeutic agents inside the cells or conjugate them on the surface.
RBCs have been used to deliver small molecule drugs, proteins, peptides, enzymes, and
nucleic acids due to their high flexibility, biodegradability, biocompatibility, prolonged
circulation time (~120 days), and limited immunogenicity[175]. However, RBCs are not
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ideal drug carriers due to the fragility of cells during the loading process and the rapid
leakage of encapsulated agents. The remarkable properties of RBCs have driven interest
in the pursuit of artificial vehicles that mimic RBCs for more efficient drug delivery. To
mimic natural RBCs, physiological and biological characteristics of RBCs, in terms of
size, shape, flexibility, and biological entities, should be considered. Doshi et al.
developed PLGA nanoparticles mimicking the shape and deformability of RBCs[176].
They first prepared RBC-shaped template PLGA using the electrohydrodynamic jetting
process, followed by a layer-by-layer self-assembly method to electrostatically deposit
polycation and polyanion pairs on the surface of particles. The assembled shell was crosslinked using glutaraldehyde and then partially fluidized by tetrahydrofuran, resulting in
the formation of soft particles with RBCs morphology.
Biological components on the surface of cells are important for many cellular functions.
RBCs express several biomarkers which have been identified as immunomodulatory
proteins to inhibit immune responses actively. For example, CD47, a 50 kDa membrane
protein, can inhibit phagocytosis by macrophages by binding the signal regulator protein
α(SIRPα)[177]. CD59 and C8-binding protein are responsible for preventing full
assembly of the membrane attack complex (MAC)[178, 179]. Those biomarkers should
also be considered in mimicking RBC for design the drug delivery system. It has been
shown that CD47 functionalized nanoparticles significantly reduced phagocytic uptake
by J774A.1 murine macrophages, which express high levels of SIRPα[180]. The
membranes of RBCs are a readily available cell source. Many studies describe the
translocation of RBC membranes onto the surface of synthetic nanoparticles, such as
polystyrene-, gold-, Fe3O4- and PLGA- nanoparticles, to avoid rapid clearance and have
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prolonged circulation[181-184]. The RBC membranes camouflaged nanoparticles were
prepared using mechanical co-extrusion to fuse RBC membrane-derived vesicles and
particles.
Another feature of cells that can motivate the design of a cell-mimicking drug delivery
system is the compartmentalization of cells. The interior of cells is compartmentalized
into various sizes of organelles, such as ribosomes, endosomes, and lysosomes. Those
intracellular multifunctional compartments are involved in a variety of processes.
Synthetic particles with multiple compartments may provide diverse characteristics as
delivery systems. For example, particles can load with a different payload in each
compartment. Compartments can be made of different materials, which may enable
independent control of drug release. Multicompartmental micelles prepared by selfassembly of triblock copolymers have been reported[185]. Kisak et al. constructed
particles with nano-compartments, called vesosomes, containing multiple vesicles,
colloidal particles, and macromolecules inside the interdigitated lipid bilayers[186].
1.6.3 Biomimetic materials
Biomaterials have been designed for drug delivery systems for over 60 years, which have
improved the delivery and efficacy of many compounds, like small molecule drugs,
proteins, antibodies, vaccines, and genes[187, 188]. Besides existing biological
substances like inactivated viral vectors, bacteria vectors, biomimetic delivery systems
are made of synthetic materials similar to biological materials. Hydrogels are a group of
natural or synthetic hydrophilic polymers capable of absorbing large amounts of water
due to chemical or physical cross-linking of polymer chains. Hydrogels can closely
resemble the natural cellular microenvironment by modifying the hydrogel matrix and
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incorporating biological entities[189]. Liposomes are spherical vesicles comprising a
phospholipid bilayer. Liposomes are non-toxic, biocompatible, and biodegradable, which
could encapsulate both hydrophobic and hydrophilic drugs. The similarity of the
liposomes to the cell membrane in humans or animals made them a potential biomimetic
drug delivery system. Zasadzinski et al. reported multi-compartmentalized liposomes,
vesosomes, which mimic compartments in cells for multi-component drug delivery[190].
Polymeric nanoparticles as biomimetic carriers have many advantages, such as high drug
loading, controllable drug release, and modification due to functional groups on the
surface. These biomimetic polymers can mimic cellular interaction with the environment
through active biological entities[191]. Nanostructures, unique adjustable hollow
structures, have been widely used in biomimetic drug delivery systems. For example,
nanofibers produced from silk fibroin and hyaluronic acid could be fabricated to mimic
the extracellular matrix (ECM) for tissue engineering[192]. Wang et al. described
eukaryotic cell-like nanoparticles for delivery of theranostic agents[193]. This
nanostructure consists of a phospholipid membrane, a cytoskeleton-like mesoporous
silica matrix, and a nucleus-like fullerene core.
1.6.4 Application of MOFs as biomimetics
MOFs are another promising material for the development of biomimetics in medicine
and pharmaceutics. Chen et al. engineered spiky, bacterium-like MOFs as photothermal
agents, which consist of aluminum (Al) and ruthenium (Ru) and a linker of 2aminoterephthalic acid[194]. These bacterium-like MOFs were more easily phagocytosed
by macrophages than are spherical and can elicit several immune-mediated functions to
modulate the immunosuppressive environment of tumors. Alyami et al. reported

35
developing biomimetic zeolitic imidazolate frameworks (ZIFs) encapsulating
CRISPR/Cas9 coated with cancer cells membrane for targeted and cell-specific
delivery[195]. Inspired by the natural multi-enzyme system, Zheng et al. developed a
novel Cu-MOF system of the co-encapsulation of glucose oxidase and L-arginine by
biomimetic mineralization to achieve synergistic bacteria killing[196]. Zhong et al. also
reported a biomimetic MOF-545(Fe) with enzyme-mimetic properties for rapid detection
of glucose[197].
In this dissertation, two types of iron-based MOFs, namely MIL-100(Fe) and MIL88A(Fe), were used as biomaterial to develop bacteria-mimicking particles. The
biomimetic strategies focused on physical properties (size and shape) and surface
modification (saccharides and lipids).
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Chapter 2 Mannose-MOFs for Macrophage Targeting

2.1 Introduction
Metal-organic frameworks (MOFs), novel crystalline hybrid materials comprised of
metal ions or clusters bridged by polydentate organic linkers, have emerged as a
promising carrier for drug delivery. MOFs have remarkable characteristics to ensure high
drug loadings, such as high porosities, tunable pore size, large surface areas, and versatile
surface functionality to interact with drug molecules [198-200]. The bio-applications of
MOFs have been intensively studied as various therapeutic agents have been loaded in
these materials [201, 202]. Taylor-Pashow et al. demonstrated MIL-101(Fe) for loading
the anti-cancer agent cisplatin [203]. McKinlay et al. used
MOF([M2(C8H2O6)(H2O)2] · 8H2O (M=Co, Ni)) to store and release the vasodilating gas
nitric oxide for antibacterial, antithrombotic, and wound healing applications [204].
Horcajada et al. showed several iron-carboxylate MOFs with engineered cores and
surfaces to encapsulate many anti-cancer and antiviral agents against cancer and
AIDS(acquired immunodeficiency syndrome)[205]. So far, only a few studies have been
found to investigate the potential of MOFs in the treatment of infectious diseases [140,
206]. Among all known MOF structures, the iron (III) carboxylate-based MOFs have
attracted increasing interest for bioapplications [202, 205]. The iron (III) fumarate
MIL‐88A and (III) trimesate MIL‐100 MOFs (MIL: Material of Institute Lavoisier) are
examples of biocompatible and biodegradable materials as assessed by thorough in vivo
toxicity studies [207].
Recent advances in bionanotechnology indicated the importance of biomimicry in
biomedical applications and drug delivery. Precisely engineered biomimetic particles
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have been applied to deliver anti-cancer drugs [208, 209] and devolvement of vaccine
adjuvants [210, 211]. A few studies have demonstrated bioengineered bacteria or
“pathogen-like” particles as antibiotic carriers for infectious diseases [212-214]. MOFs’
unique crystalline structure and surface functionality make them attractive biomimetic
micro-and nano-particle delivery platforms. The bipyramidal hexagonal prism and
octahedral shapes of MIL-88A(Fe) and MIL-100(Fe) crystals can provide defined rodlike and spherical particles, mirroring the main basic shapes of bacteria. For example,
Mycobacterium, Yersinia pestis, and Bacillus anthracis, which cause tuberculosis, plague,
and anthrax, respectively, are rod-shaped. Staphylococcus aureus often causes skin
infections, and Neisseria meningitidis, the primary cause of bacterial meningitis, are both
spherical. One common approach to form “pathogen-like” particles is to functionalize
particles with bacterial outer components, such as sugars (e.g., mannose, fucose, and
glucan), peptidoglycans, lipopolysaccharides, etc. Mannose is often found on the surface
of many respiratory pathogens, such as Yersinia pestis, Streptococcus
pneumonia, Mycobacterium tuberculosis, and influenza virus [215-218]. Alveolar
macrophages (AMs) are the predominant resident host defense cells in the lungs against
infection by these pathogenic microbes. Mannose receptor (MR, CD206), which belongs
to the C-type lectin family, is found in most tissue macrophages, dendritic cells and select
hepatic and lymphatic endothelia [219]. MR is also highly expressed in AMs [220], and it
has been reported that MR mediated the recognition, binding, and internalization of many
pathogens by AMs [221-224]. Macrophages can recognize and interact with pathogens
and, in the same manner, “pathogen-like” particles, opening a new perspective on treating
infectious diseases. For example, Chavez-Santoscoy et al. developed mannose-
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functionalized“pathogen-like” nanoparticles targeting C-type receptors on AMs [225].
Also noteworthy is that the treatment of infectious diseases such as tuberculosis, leprosy,
legionnaires, or toxoplasmosis is often associated with poor efficiency by conventional
therapy, increasing the risk of developing antibiotic resistance and clinical relapses. This
is because these pathogens (e.g., Mycobacterium tuberculosis, Mycobacterium leprae,
Legionella pneumophila, Toxoplasma gondii) can use macrophages as host cells to
survive and multiply. Many mechanisms involved include blocking phagolysosome
formation and phagosome maturation, promoting fusion of endosomes with cell
organelles other than lysosomes, disrupting endosomes and escaping into the cytosol, etc.
[226].
Although MOFs are a promising biomimicry delivery platform, there is little information
about how MOFs interact with macrophages and how their properties, such as shape, size,
and surface modification, impact this interaction. Therefore, understanding the role and
significance of physicochemical properties is vital for the further biomimetic application
of MOFs. This chapter aims to investigate the new potential application of MOFs (MIL88A(Fe) and MIL-100(Fe)) with various properties as drug delivery vehicles for
infectious disease applications. The fluorescently labeled MIL-88A(Fe) and MIL-100(Fe)
were modified with mannose to model “pathogen-like” particles. The internalization
kinetics, endocytosis mechanism, and intracellular fate of these particles were studied in
3D4/21 swine alveolar macrophages. This strategy may provide a new paradigm of
MOFs in biomimicry applications.
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2.2 Materials and methods
2.2.1 Synthesis of MOF particles
2.2.1.1 MIL-100(Fe)
MIL-100(Fe) metal-organic frameworks were synthesized by a microwave-assisted
solvothermal route as previously described[227]. 6.0 mM of iron (III) chloride
hexahydrate and 4.0 mM trimesic acid was dissolved in 30 mL water. The mixture was
introduced into the microwave oven and heated to 130 °C for 6 min with a power of 1600
W. The reacting mixture was cooled down to room temperature and centrifuged at 10,000
g for 15 min. The solvent was removed, and the orange pellet was then washed with 20
mL absolute ethanol to remove the excessive trimesic acid. MIL-100(Fe) was stored in
absolute ethanol at room temperature for further usage.
2.2.1.2 MIL-88A(Fe)
MIL-88A (Fe) metal-organic frameworks were synthesized by a microwave-assisted
hydro-solvothermal approach based on Chalati et al.work[228]. 40 mM of iron (III)
chloride hexahydrate and 40 mM of fumaric acid was dissolved in 10 mL water. The
reaction mixture was then placed into a microwave oven, heated to 80 °C (600W) under
continuous stirring for 10 min. The resulting precipitate was cooled down to room
temperature and recovered by centrifugation at 10,000 g for 15 min. To remove the free
acid, the pellet was washed with 20 mL of absolute ethanol three times. MIL-88A(Fe)
was stored in ethanol at room temperature for further usage.
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2.2.2 Characterization of MOF particles
2.2.2.1 X-Ray Powder Diffraction (XRPD)
Powder X-ray diffractograms of MIL-100(Fe) and MIL-88A(Fe) were generated on a
Siemens D5000 diffractometer using Cu Kα1,2 radiation (λ=1.5406Å). The pattern was
recorded within the 3 – 40° (2θ) range, with a step of 0.02° and 4 s per step in continuous
mode.
2.2.2.2 Thermogravimetric Analysis (TGA)
Thermogravimetric measurements were performed on a thermogravimetric analyzer
(Perkin Elmer Diamond TGA/DTA STA 6000). 5-10 mg samples were heated from room
temperature to 600 °C with an oxygen flow of 200 ml/min.
2.2.2.3 Fourier Transform Infrared Spectroscopy (FT-IR)
A JASCO FT-IR 6800 spectrophotometer investigated the structural characterization of
MOF particles. Each spectrum was collected at room temperature, scanned in the spectral
region of 4000–500 cm−1, and analyzed using JASCO Spectra Manager™ II crossplatform software.
2.2.2.4 Nitrogen sorption isotherms (NSP)
The N2 adsorption-desorption isotherms were measured on BELSORP-miniII (Bel, Japan)
at liquid nitrogen temperature (77 K). Prior to the analysis, samples were dried for 6 h at
T=150°C under primary vacuum. BET (the Brunauer, Emmett, and Teller) surface was
determined at a relative pressure below 0.25. Surface area and pore size of MOF particles
were calculated by BET method and density functional theory (DFT) based on N2
adsorption-desorption data. Samples were degassed in a vacuum for 12 h before the
measurement.
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2.2.2.5 Dynamic Light Scatting (DLS)
The mean hydrodynamic diameter of MIL-100 (Fe) and zeta-potentials of pure MOFs
and modified MOFs were determined using Zetasizer, Nano-ZS (Malvern). Prior to
analysis, particles were suspended in distilled water at 50µg∙mL-1 and sonicated under
ultrasound for 10 min.
2.2.2.6 Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM) analysis was performed using a JEOL JSM-7001F
microscope equipped with an energy-dispersive X-ray (EDX) spectrometer and an XMax SDD (Silicon Drift Detector) by Oxford. Samples were placed onto carbon support
and then sputter-coated with gold before observation under SEM. The specimen was
imaged at a voltage of 15 keV. Over 120 MOF particles from 5 different images were
randomly selected, and their aspect ratio and particle size were measured using ImageJ
version 1.42v software (National Institutes of Health, Bethesda, MD).
2.2.3 Fluorescent labeling of MOFs
2.2.3.1Method
The feasibility of engineering the outer surface of MOFs by covalent attachment with
molecules containing amino groups through EDC/NHS coupling was previously
reported[229]. 10 mg MOFs (MIL-100(Fe) or MIL-88A(Fe)) were dispersed in 2 mL of
5 mM HEPES buffer (pH 7.4) and sonicated for 2 min. Then, 3.2 mg EDC and 4 mg
NHS were dissolved in 400 μL of HEPES and added dropwise into the MOF suspension
followed by 30 min stirring at room temperature. Then, 200 μL of sulfo-Cy5-NH2 in
anhydrous DMSO (2 mg∙mL−1 for MIL-100(Fe) and 4 mg∙mL−1 for MIL-88A(Fe)) was
added to the mixture and stirred for 2 h at room temperature. After the reaction, particles
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were collected by centrifugation at 20,000×g for 30 min and washed with ethanol and
water to remove the unreacted dye. Fluorescently labeled MOFs (Cy5-MOFs) were then
collected by centrifugation as mentioned above and lyophilized for 24 h.
2.2.3.2 Quantification
The labeling ratio (%w/w) was determined by measuring fluorescent intensity of sulfoCy5-NH2 solution (λex = 649 nm, λem = 666 nm) after decomposition of fluorescently
labeled MOFs by incubation in 100 mM citrate buffer (pH 5.5) at 40°C for 24 h and
compared with a calibration curve of free dye. The concentration of Cy5-NH2 stock
solution was 2 µg∙mL-1. Serial two-fold dilutions were prepared, and their fluorescent
intensity was measured by Synergy H4 Multi-Mode Microplate Reader (Bio-Tek,
Winooski, VT). Dilutions of a standard dye stock solution (2 µg∙mL-1) with
corresponding fluorescent intensities which fall within the linear range of the dye
calibration curve are chosen. The dilution factor for samples was determined empirically
to obtain fluorescence intensity within the linear range.
2.2.4 Mannose modification of MOFs
2.2.4.1 Method
Fluorescently labeled MOFs hereafter called Cy5-MOFs (Cy5-MIL-100 or Cy5-MIL88A) were dispersed in 5 mM HEPES buffer (pH 7.4) to final concentration 0.37 mg/mL
and sonicated for 2 min at room temperature. Then, 1.6 mg EDC and 1.9 mg NHS were
added dropwise to 13.4 mL of Cy5-MOF suspension and stirred for 15 min. Then, 2.6 mg
of mannosamine hydrochloride in 200 μL anhydrous DMSO was added to the mixture,
followed by overnight stirring at room temperature. After mannosylation, particles were
collected by centrifugation at 20,000×g for 30 min and washed three times with 14 mL of
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water. After each centrifugation, supernatant with unreacted mannosamine after reaction
and washing steps was kept to detect unreacted mannosamine further. Mannsolyated
MOFs particles were defined as MIL-100(Fe)-Cy5-Man or MIL-88A(Fe)-Cy5-Man. To
study whether mannosamine would be encapsulated in MOFs, a control was conducted
by the same procedure mentioned above without the EDC/NHS coupling reaction.
Instead, mannosamine was directedly added into Cy5-MOF suspension. After thoroughly
washing, MOF particles were collected and lyophilized. The MOFs underwent
decomposition in 100 mM citrate buffer (pH 5.5) at 40°C in the incubator overnight, and
then the solution was kept for detection of encapsulated mannosamine.
2.2.4.2 Quantification
Mannosylation ratio (% w/w) was determined using a previously described colorimetric
method based on the detection of unreacted mannosamine [230]. For this aim, 100 μL of
supernatant after nanoparticle collection was mixed with 30 μL of solution of
fluorescamine in DMSO (3 mg∙mL−1). The fluorescence intensity was measured using a
96-well plate spectrophotometer SpectraMax M2 (Molecular Devices) at λex = 395 nm
and λem = 495 nm. Standard solutions of mannosamine were prepared in HEPES buffer.
Compared with the calibration curve of free mannosamine, the concentration of
mannosamine in all supernatant samples was determined. The dilution factor for the
sample was determined empirically to obtain fluorescence intensity within the linear
range.
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The labeling ratio of mannosamine on MOFs (P; % w/w) was calculate

=

+

100
Equation 2.1

Wattached mannose=Winitial−Wsupernatant
where Winitial is the weight of mannosamine at the beginning of the reaction, Wsupernatant is
the weight of unreacted mannosamine, and WMOFs is the weight of MOFs.
2.2.5 Cell culture
3D4/21 swine alveolar macrophages (ATCC, CRL-2843) were cultured in RPMI 1640
medium containing 2 mM L-glutamine and supplemented with 10 mM HEPES, 1.0 mM
sodium pyruvate, 1% PenStrep, 90% 0.1 mM nonessential amino acids, and 10% fetal
bovine serum. Cells were grown in a humidified atmosphere of 5% CO2 at 37°С.
Passages 6–10 were used in this study.
2.2.6 Cellular viability
Cellular viability in the presence of inhibitors and MOFs was assessed using an MTT
assay. 3D4/21 cells were seeded on 96 well plates at an initial density of 5000 cells/well
and cultured overnight. Cells were treated with varying concentrations (0.1,1,2,5,10, 20,
50,100 µg∙mL-1), of MIL-88A(Fe) and MIL-100(Fe) particles for 24 h to evaluate
cytotoxicity. Cells were also treated with varying concentrations of cytochalasin D
(0.1,1,2.5,5,7.5,10,25, 50µM), chlorpromazine (0.1,1, 2.5, 5, 7.5,10, 25, 50µM), or
sodium azide (0.1,1,2.5,5,7.5,10,25, 50 mM), for 8 h to determine non-toxic
concentrations for inhibitory analysis. After the incubation period, 20 µL/well MTT

45
reagent (5mg∙mL-1) was added to each well for 4 h in the dark at 37°C until purple
formazan crystals were visible under a microscope. The medium was removed, and 100
µL solubilization solution (DMSO/EtOH, 1:1) was added to each well. The plates were
placed on an orbital shaker (200rpm) for 30 min to enhance the dissolution of purple
crystals. The absorbance of samples was measured at 560 nm using Synergy H4 MultiMode Microplate Reader (Bio-Tek, Winooski, VT). The reference absorbance at 650nm
was used to correct nonspecific background. The 650 nm absorbance values were
subtracted from the 560nm absorbance values of corresponding experimental wells. The
relative cell viability (%) for the negative control (100% cell viability) was determined.
2.2.7 Intracellular reactive oxygen species (ROS)
3D4/21 cells were seeded in a 96-well plate at a density of 5000 cells/well. Cells were
incubated with MIL-100(Fe) and MIL-88A(Fe) at a serial concentration of
0.1,1,2,5,10,20,50, and 100 µg∙mL-1 for 24 h. After exposure to MOFs, the supernatant
was removed, and cells were washed twice with warmed HBSS (GibcoTM). 2′,7′Dichlorofluorescin diacetate (DCFH-DA; Sigma) was dissolved in DMSO to a final
concentration of 1mM and diluted in HBSS. Cells were incubated with 10 µM DCFHDA for 30 min at 37°С. Fluorescence intensity was measured by GloMax®-Multi
Detection System (Promega, Madison, WI) equipped with a blue optical kit (λex = 470 nm,
λem = 510-570 nm)
2.2.8 MOF particle uptake
3D4/21 cells were seeded in 24-well plates at a density of 6 × 104 cells/well and cultured
for 48 h. MIL-100(Fe)-Cy5 ± Man or MIL-88A(Fe)-Cy5 ± Man particles were added at a
final concentration of 5 μg∙ mL−1 and 20 μg ∙mL−1 per well, respectively. After incubating
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MOFs for 2 h, 5 h, 8 h, 12 h, and 18 h, the growth medium was removed, and cells were
washed with HBSS. Cells were dispersed with 75 μL per well of 0.25% trypsin in 37°С
incubator for 15 min, suspended in 500 μL Versene solution per well and collected in
2.0 mL microcentrifuge tubes. Following centrifugation at 500×g for 30 s, cells were
resuspended in 300 μL of Versene solution containing 1 μg mL−1 propidium iodide to
differentiate live and dead cells. The intensity of nanoparticles internalized by cells was
measured using a BD Accuri™ C6 Plus flow cytometer (BD Biosciences) equipped with
a 640 laser in a 625-675 nm channel. Over 10,000 events were gated per sample. Samples
were prepared in quadruplicate.
2.2.9 Endocytosis pathway
3D4/21 cells were seeded in 24-well plates at a density of 6 × 104 cells/well and cultured
for 48 h. Cells were pretreated with 5 μM cytochalasin D, 10 μM chlorpromazine, or
50 mM sodium azide for 30 min prior to the addition of MOF particles. After incubation
of MOFs for 8 h, the growth medium was removed, and cells were washed with HBSS.
Sample preparation, flow cytometry, and data collection followed the same procedure as
described in Section 2.2.8.
2.2.10 MOF particle localization in 3D4/21 cells
3D4/21 cells were seeded onto POC mini chambers (PeCon, Germany) with 5 × 105 cells
per chamber in 1 mL growth medium and cultured for 24 h in a humidified atmosphere of
5% CO2 at 37°С. Then, cells were incubated with either MIL-100(Fe)-Cy5-Man or MIL88A(Fe)-Cy5-Man particles, added at a final concentration of 10 μg∙mL−1, and incubated
for 5 h. Prior to confocal laser scanning microscopy, Hoechst 33342 and LysoTracker
Green DND-26 were added to 3D4/21 cells at final concentrations of 1 μg∙mL−1 and
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75 nM, respectively. An Olympus FV1200 laser scanning microscope equipped with
a × 100/1.4 oil objective lens was used for image acquisition. Cell images were obtained
using an excitation wavelength of 405 nm for Hoechst (425–475 nm passband for
emission), 488 nm for LysoTracker Green (500–545 nm passband for emission), and
635 nm excitation for Cy5 (655–755 passband for emission). The quantification of
colocalization was determined by Mander’s overlap coefficient using Image J version
1.42v software (National Institutes of Health, Bethesda, MD).

2.3 Results and discussion
2.3.1 Synthesis and characterization of MOF particles
Different synthetic strategies can be applied to obtain the desired size and morphology of
MOF particles. MIL-100(Fe) was synthesized at low temperature (<100°C), and
atmospheric pressure was mainly octahedral in shape[231]. MIL-100(Fe) obtained with
water/ethanol(80:20) mixture exhibited two-thirds of BET specific surface area compared
to those synthesized with water only[227]. It is reported that three kinds of
crystallographic structures of MIL-88A(Fe), such as rod-like, spindle-like, and diamondlike structures, can be prepared using a solvothermal process with different solvents [232].
The synthesis of MIL-100(Fe) and MIL-88A(Fe) was performed according to previously
published procedures[227, 228]. Both microporous flexible MIL-88A
(Fe3O(OH)[C2H2(CO2)2]3) and mesoporous rigid MIL-100
(Fe3O(OH)(H2O)2[C6H3(COO)3]2) are built up from oxo-centered trimers of iron (III) in
octahedral coordination that is bridged by fumaric or trimesic acids, respectively (Fig 2.
1a and b). SEM image shows that particles of MIL-88A(Fe) had rod-like shapes, and the
size was ranging from 3-5 µm in length with an aspect ratio of 1:5, whereas particles of
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MIL-100(Fe) were spherical with a z-average diameter of 100 nm (Fig 2.1c). The mean
diameter of MIL-100(Fe) measured by DLS was approximately 300 nm (Fig 2.7a)

Figure 2.1 Crystalline structure and images of MOFs. (a) Scheme of MIL-88A(Fe)
structure and post-synthesis modifications; Fe (III) octahedra indicated in orange, oxygen
in red, carbon in gray, nitrogen in blue, mannosamine in purple, Cy5 dye in green; H
atoms have been omitted for clarity. (b) Scheme of MIL-100(Fe) structure; Fe (III)
octahedra indicated in green, oxygen in red, carbon in gray; H atoms have been omitted
for clarity. The pore volume of the MIL-100(Fe) mesoporous cavity is represented by
yellow sphere. (c) SEM images of MIL-88A (Fe) and MIL-100(Fe) nanoparticles; scale
bars are 3 µm for MIL-88A(Fe) and 100 nm for MIL-100(Fe).
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Obtained materials were characterized using X-ray powder diffraction, infrared
spectroscopy analysis, thermogravimetric analysis, and nitrogen sorption porosimetry.
The presence of characteristic diffraction peaks confirmed the MIL-100 (Fe) and MIL88A(Fe) crystalline structures. As shown in Fig 2.2, the main diffraction peaks of assynthesized MIL-100(Fe) and MIL-88A(Fe) are in good agreement with those reported in
the literature [37-40].

Figure 2.2 XRD patterns of (a) MIL-100(Fe) and (b) MIL-88A(Fe).
Figure 2.3 presents the FT-IR spectrums of MIL-100(Fe) and MIL-88A(Fe). The
significant bands of the MIL-100(Fe) are attributed to -OH stretching(3400cm-1), -C

O

stretching vibration (1630cm-1), -OH vibration(1450cm-1), -C-O stretching vibration
(1360cm-1), C

C stretching vibrations in benzene ring (758cm-1 and 709cm-1) and Fe-O

stretching vibrations (487cm-1)[233, 234]. In the spectrum of MIL-88(Fe), the bands at
1400 and 1600 cm−1 can be attributed to the symmetric and asymmetric carboxyl group
(−COOH) stretching vibration, respectively, and band at 550 cm−1can be assigned to the
stretch vibration of Fe-O[235-237].
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Figure 2.3 FT-IR spectrum of (a) MIL-100(Fe) and (b) MIL-88A(Fe).

As can be seen from thermogravimetric analysis in Fig 2.4, both MIL-100(Fe) and MIL88A(Fe) showed two-stage weight loss. MIL-100(Fe) and MIL-88A(Fe) had
approximately 75% and 65% total weight loss, respectively. The first stage (below
100 °C) can be attributed to the loss of the residual water insides the pores. The second
stage of a sharp weight loss occurred at 275 °C to 350°C for MIL-100(Fe), and at 225°C
to 300°C for MIL-88A(Fe) is related to linker decomposition with the framework.

51

100

a

b

100%
90%

Weight loss, %

Weight loss, %

80

60

40

80%
70%
60%
50%
40%

20

30%
20%

0
0

100

200
300
400
Temperature, °C

500

0

600

100

200

300

400

500

600

Temperature (°C)

Figure 2.4 Thermogravimetric analysis profile of (a) MIL-100(Fe) and (b) MIL-88A(Fe).
The N2 adsorption-desorption isotherm of MIL-100(Fe) displayed a typical type- I shape,
indicating microporous structure (Fig 2.5a). The BET-specific surface area of MIL100(Fe) and MIL-88A(Fe) was 1543 m2g-1 and 62 m2g-1, respectively. The mean pore
diameter of MIL-100(Fe) and MIL-88A(Fe) were 2.5-2.7 nm and 0.5-0.7 nm,
respectively.
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Figure 2.5 Nitrogen sorption isotherm of (a) MIL-100(Fe) and (b) MIL-88A(Fe).
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2.3.2 MOF modification and characterization of functionalized MOF particles
MOFs have been widely explored in the application of gas storage [238], gas/vapor
separation [239], catalysis [240], and biomedicine [202, 241] due to their diverse
structure types, tunable porosity, large surface area, high drug loading, and
biocompatibility. To expand the unique properties of MOFs, surface engineering has
become of increasing research interest. Several approaches have been developed to attach
a desired functional unit to the MOF surface, including the use of capping molecules
during MOF synthesis [242, 243], covalent [244], and non-covalent [245-247] postsynthesis modification. Fe (III) carboxylates MIL-88A(Fe), and MIL-100(Fe) possess
both Lewis acid sites and terminal carboxylic groups on their outer surface that are
available for surface modification. The covalent conjugation of sulfo-Cy5-NH2 and
mannosamine to MIL-88A(Fe) and MIL-100(Fe) particles was successfully achieved by
EDC/NHS coupling reaction (Fig 2.1a). MOF particles depended on EDC/NHS to
activate the carboxyl groups on their surface to form MHS ester intermediates that can
subsequently react with primary amine groups on the dye or surface ligands. EDC/NHS
coupling has been previously applied to modify the outer surface of MIL-100(Fe) [229].
A main advantage of EDC/NHS coupling is its water-based condition without prior
organic solvent dissolution and short time frame. The reaction was performed under pH
7.4 to minimize risk of hydrolysis. As for the selection of fluorophore, water solubility,
pH-independence in physiological pH range (from pH 4 to 10), and molecular
size/weight were taken into consideration. However, sufficient washing is still required in
this protocol to remove all excess reagents, free-dye, and unreacted molecules. Figure
2.6 (a) shows the Cy 5 fluorescence intensities standard curve with a regression value of
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0.9991. According to the equation (y = 397.53x + 1.1566), the amount of dye conjugated
on MOFs was calculated. The fluorescent labeling ratios of MIL-88A(Fe) and MIL100(Fe) were 0.06% w/w and 0.33% w/w, respectively.
MOF particles were then modified with mannosamine to further bind to the mannose
receptor on macrophages. The amount of unreacted mannosamine in each wash step was
calculated based on the equation (y= 47484x + 413.55, R² = 0.9988) in Fig 2.6 b.
Mannosylation ratio (% w/w) was 19.7% and 15.1% for MIL-88A(Fe) and MIL-100(Fe),
respectively. Since the mannosamine molecule is small enough to pass through
microporous apertures of MIL-88A(Fe) and MIL-100(Fe), several washing steps were
needed to ensure its successful removal. The absence of mannosamine in the supernatant
after the last wash was confirmed by colorimetric measurement. The same method was
also performed to detect potentially encapsulated mannosamine. The experiment was
conducted under the same condition and procedure except for EDC/NHS coupling
reaction, which means no surface modification with mannosamine would happen.
Particles were washed three times with water, dried, and then destroyed in 100mM citrate
buffer. The following equation calculated the loading capacity:

=

+

100

Equation 2.2
Negligible amounts of unreacted mannosamine were found to be encapsulated in MIL100(Fe) (0.5%) and MIL-88A(Fe) (0.15%). The result indicates that a substantial amount
of mannosamine was on the MOFs’ surface, not within the MOFs’ pores. The zeta
potential of Cy5-MOF slightly shifted, indicating the achievement of mannosylation. The
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hydrodynamic diameter of mannosylated MIL-100(Fe) remained compared to nonmannosylated ones (Fig 2.7). Physicochemical characteristics of native MOFs and MOFs
with the modified surface are summarized in Table 2.1.

Figure 2.6 The standard curve of the fluorescent intensity of (a)Cy5 in 100mM citrate
buffer and (b)mannosamine in water.
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Table 2.1 Physicochemical Characteristics of MOF Nanoparticles.
MOF

MIL-88A-Cy5

MIL-88A-Cy5-Man

MIL-100-Cy5

MIL-100-Cy5-Man

Organic linker

Fumaric acid

Trimesic acid

Unit Formula

Fe3O(OH)[C2H2(CO2)2]3

Fe3O(OH)(H2O)2[C6H3(COO)3]2

Pore size(Å)

5-7

25-27

Aspect ratio

1:5

1:1

Particle size(nm)

3628 ± 573*

103.9±7.2*

307.9 ±32.1‡

295.7 ± 15.0‡
PDI †
Zeta potential

7.3±0.6

12.1±2.0

0.254

2.263

-25.9±0.5

-20.9±0.8

(mV)
0.06

Fluorescent

0.33

labeling
(% w/w)
Labeling with

-

19.7

-

15.1

mannosamine
(% w/w)

The values are given as means±SD. *Measured by SEM for MIL-88A(Fe) and MIL100(Fe), respectively. For MIL-88A(Fe) particles, the values are given for the long axis.
‡

Measured by DLS for MIL-100(Fe) and MIL-100-Man. †PDI values are given for the

diameter of MIL-100(Fe) particle by DLS.
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Figure 2.7 DLS distribution of (a)MIL-100(Fe) and (b)MIL-100-Man (Fe).

2.3.3 Cytotoxicity and ROS generation
The cytotoxicity of MOF highly depends on MOF composition, metals, and organic
linkers. MIL-100(Fe) and MIL-88A(Fe) have carboxylic acid linkers that are less toxic
and easily removed. The nature of the metals could damage the cells through the
formation of reactive oxygen species (ROS). Many studies have shown that iron
carboxylate MOFs exhibit good biocompatibility and low cytotoxicity. MIL-100(Fe) and
MIL88A(Fe) were evaluated for their cytotoxicity against 3D4/21 swine alveolar
macrophage. Considering that alveolar macrophages are critical for the clearance of
inhaled bacterial pathogens, the synthesized MOFs should not be toxic to the host cells.
The MTT results show that MOFs were non-toxic for the 3D4/21 cells up to 100 µg∙mL-1
with 80% and 90% cell viability for MIL-100(Fe) and MIL-88A(Fe) in 24 h (Fig 2.8).
The level of oxidative stress is related to the cytotoxicity of materials. As concentrations
of MOF increased, the ROS level gradually increased (Fig 2.9). MIL-88A(Fe) and MIL100(Fe) induced ROS levels comparably at concentrations below 50 µg∙mL-1. Although
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at 100 µg∙mL-1, ROS level in MIL-88A(Fe) was nearly 2-fold as MIL-100(Fe), the high
ROS value did not significantly affect cell viability over 24 h.
Tamames-Tabar et al. [248]investigated the cytotoxicity of a series of MOF particles,
including MIL-100(Fe) and MIL-88A(Fe), by MTT assay using human cervical
carcinoma (Hela) and murine macrophage (J774) cell lines. They concluded that Febased MOFs are less toxic compared with the Zr- or Zn-based MOFs. Grall et al. [249]
investigated the cytotoxicity of MIL-100(Fe, Cr, and Al) on lung epithelial human cell
lines (A549 and Calu-3) and hepatic epithelial human cell lines (HepG2 and Hep3B) by
measuring cell impedance, cell death, ROS generation and the level of DNA damage.
They found that MIL-100 did not induce cell toxicity and only the toxic effect of MIL100(Fe) particles in the Hep3B cell line. Strzempek et al. [250] tested the cytotoxic effect
of MIL-100(Fe) on A549 epithelial and RAW 246.7 macrophages cells. They concluded
that MIL-100(Fe) is biocompatible and does not show a significant cytotoxic effect. Zhao
et al. [251] showed no cytotoxicity of MIL-88A(Fe) was observed in 293T cells even
with a concentration of 100µg∙mL-1. Based on the non-toxic concentration range and
fluorescent labeling ratio, 5 μg∙ mL−1 for MIL-100(Fe) and 20 μg ∙mL−1 for MIL-88A(Fe)
were chosen for MOFs uptake experiments.
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Figure 2.8 MTT assays of 3D4/21 cell viability after 24 h exposure to (a) MIL-100(Fe)
or (b) MIL-88A(Fe) Data are given as means±SD.

Figure 2.9 Intracellular reactive oxygen species level in 3D4/21 cells induced by (a)
MIL-100(Fe) and (b) MIL-88A(Fe), measured as the fluorescence intensity of 2′,7′Dichlorofluorescin diacetate (DCFH-DA). Data are given as means±SD.
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According to the cytotoxicity of inhibitors on 3D4/21 cells shown in Fig 2.10 and
observed changes in cell morphology, 5 μM cytochalasin D, 10 μM chlorpromazine, or
50 mM sodium azide were chosen to have sound inhibitory effects with desirable cell
viability.

Figure 2.10 MTT assays of 3D4/21 cell viability after 8 h exposure to inhibitors of
endocytosis such as (a) chlorpromazine, (b) sodium azide, or (c) cytochalasin D. Data are
given as means±SD.
2.3.4 Uptake kinetics in 3D4/21 cells
The particle size, shape (aspect ratio), and surface chemistry play crucial roles in
macrophage uptake [252-254]. Here, the combinatorial effects of MOF particles’
physicochemical properties on uptake were demonstrated using 3D4/21 alveolar
macrophages. The uptake kinetics of MIL-88A(Fe)-Cy5±Man or MIL-100(Fe)-Cy5±Man
particles in 3D4/21 cells were measured using flow cytometry. Cellular uptake was
presented as fluorescence intensity per cell and the faction of positive cells. Overall, the
internalization of MOFs particles in 3D4/21 cells increased over time to a different extent.
As expected, the uptake of mannosylated MIL-88A(Fe)-Cy5 particles was markedly
higher than that of non-modified counterparts with a 5-fold difference after 18 h (Fig
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2.11a). However, there was no difference in uptake kinetics between mannosylated and
non-mannosylated MIL-100(Fe)-Cy5 (Fig 2.11b).

Figure 2.11 Cellular uptake of MIL-88A(Fe)and MIL-100(Fe) particles by 3D4/21 swine
alveolar macrophages. (a) The internalization kinetics of mannosylated MIL-88A(Fe) and
its non-mannosylated counterpart; (b) The internalization kinetics of mannosylated and
non-mannosylated MIL-100(Fe)-Cy5; (c) The fractions of fluorescently positive cells in
MIL-100(Fe)-Cy5 ± Man and MIL-88A(Fe)-Cy5±Man particles.
Fig 2.11 c shows the percentage of total cells containing MOF particles (fluorescently
positive cells) at each time point. After 2h incubation of MIL-100(Fe)-Cy5 and MIL100(Fe)-Cy5-Man nanoparticles, more than 90% of 3D4/21 cells were involved in the
internalization of particles, and around 8 h the fraction of fluorescent cells reached 100%.
As for MIL-88A(Fe) -Cy5and MIL-88A(Fe)-Cy5-Man particles, the fractions of
fluorescently positive cells only reached 13 % and 45 % of the cell population after 18h,
respectively.
The changes between cellular uptake levels of MIL-88A(Fe)-Cy5 and MIL-88A(Fe)Cy5-Man particles can be clearly illustrated by the images of 3D4/21 cell number
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distributions depending on Cy5 fluorescence intensity per cell (Fig 2.12a) and
microscopy images of 3D4/21 after 5 h incubation with MIL-88A(Fe)-Cy5 and MIL88A(Fe)-Cy5-Man particles (Fig 2.12b). To understand how mannosylation influences
macrophage uptake of MIL-88A(Fe)-Cy5±Man particles, the fractions of cells displaying
high, medium, and low Cy5 fluorescent intensity changed over time were measured (Fig
2.13a and b). Figure 2.13c illustrates how the low, medium and high proportions of
fluorescence intensity were defined. First, the signal in the control group (no treatment of
MOF) was set up as a baseline. The absolute fluorescent signal, which was between
baseline and 10000, was considered a low-intensity part. The signal between 10000 and
50000 and over 50000 was defined as medium intensity and high intensity. The cell
number in each category was counted, and the percentage of each part over the total cell
numbers was calculated. The cell fraction of high and medium fluorescent intensity in
MIL-88A(Fe)-Cy5 slightly increased over 18 h, whereas the percentage of high signal in
MIL-88A(Fe)-Cy5-Man increased considerably, and the medium proportion remained
unchanged. Combined with the results of total positive cells over time, surface decoration
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of MIL-88A(Fe) particles with mannose can improve 3D4/21 cell uptake and involve
more cell participation in particles uptake. After 12 h internalization of MIL-88A(Fe)Cy5 particles, its kinetics reached a plateau while MIL-88A(Fe)-Cy5-Man particles
continued being taken up by cells, and uptake efficiency also improved since the highintensity fraction significantly increases.

Figure 2.12 Cellular uptakes of MIL-88(Fe) by 3D4/21 cells after 5h incubation (a) Cy5
positive cell number distributions; (b) Microscopy images of 3D4 cells stained with
Hoechst 33342 (blue nuclei) with MIL-88A(Fe)-Cy5 or MIL-88A(Fe)-Cy5-Man (red
particles). Scale bars are 100 µm.
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Figure 2.13 The cell fractions of high, medium, and low Cy5 fluorescent intensity over
time in case of (a)MIL-88A(Fe)-Cy5 or (b) MIL-88A(Fe)-Cy5-Man nanoparticles,
respectively. The value of 100 % corresponds only to the cell population that internalized
nanoparticles (Cy5 fluorescently positive cells). Each measurement was carried out in
quadruplicate; over 10,000 events were gated per one measurement. Data are shown as
means ± SEM. (c) illustration of the determination of low, medium, and high
fluorescence intensity.
Of note, surface modification with mannose had no opportunity to improve the
internalization of MIL-100(Fe) nanoparticles as its rate and extent of uptake already
reached very high levels (Fig 2.11b). There was a significant increase in uptake in terms
of mannosylated-MIL-88A(Fe) particles (Fig 2.11a). Kolhar et al. found that rod-shaped
particles appear to adhere more effectively to cells compared with their spherical
counterparts [255]. The radius of curvature of rods is much higher than that of spheres
which increases the available functionalized area on particles with which cells can
interact. The rod-shaped particles, MIL-88A(Fe), have a larger radius of curvature;
therefore, mannose surface coating can facilitate the ligand-to-receptor interaction that
leads to more effective internalization [256]. Champion et al. investigated the
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dependence of phagocytosis on size by alveolar macrophages using particles ranging in
diameter from 1 μm and 6 μm. They found that particles 2-3 μm exhibited the highest
phagocytosis and attachment based on the number of contact points of particles with cells
[257]. MIL-88A(Fe) particles are more advantageous as a drug delivery system compared
with MIL-100(Fe) for macrophage-targeted therapy for several reasons. First, MIL88A(Fe) particles possess the size range and shape of the most found bacteria in nature,
which might play an important role in the initial recognition step. Additionally,
attachment of the active ligand, mannose, on the surface highly increased cell
involvement and uptake
Bacteria are the leading cause of infectious diseases, and intramacrophagic pathogens
reduce the efficiency of current therapy. The synthesized MIL-88A(Fe) and MIL-100(Fe)
particles resembled rod-like and spherical shapes of bacteria and were further
incorporated with targeting functionality. This could facilitate the recognition and
internalization by macrophages. No anti-infectious drugs were loaded at this stage, but
efficient delivery of agents has been achieved in many MOF-based particles. Recently,
Wyszogrodzka et al. evaluated the potential of MIL-101-NH2 (Fe) as a theranostic drug
delivery system for anti-tuberculosis treatment [140]. Taherzade et al. synthesized nanosized MIL-100(Fe) to encapsulate antibiotics to treat bacterial infections [206]. They
mainly investigated the applicability of MOFs as drug carriers in terms of drug loading,
drug release, and cytotoxic safety. Little studies have explored how shape, size, and
surface modification of MOFs influence cellular internalization. However, one major
limitation in our study is that cellular uptake efficiency between MIL-88A (Fe) and MIL100(Fe) cannot be directly compared due to the different fluorescent labeling ratios,
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absolute size, and/or volume of the particles. The results show that MIL-100(Fe)-Cy5
nanoparticles were rapidly internalized by most cells within 2 h, whereas the rate of
uptake of MIL-88A(Fe)-Cy5 particles was much slower, and only a small portion of cells
were involved (Fig 2.11c). Yue et al. found that the internalization of nanosized particles
by macrophages occurred immediately within 1h, whereas the uptake of microparticles
exhibited a lag phase at the beginning [258]. Therefore, it is not surprising that MIL100(Fe) particles, having a diameter of approximately 100 nm, were readily taken up by
macrophages. MIL-88A(Fe) particles are micron-scaled and rod-shaped, of which
internalization likely depends on the shape and its point of initial attachment to the cell
surface (local geometry), as has been seen for other rod-shaped particles [259]. The high
aspect ratio and orientation may prevent cells from completing phagocytosis and retard
the rate of internalization [260].
2.3.5 Mechanism of endocytosis pathway
Since little has been done to elucidate the endocytosis mechanism of MOF particles by
AMs, the MOFs uptake pathways were investigated by exposure to specific chemical
inhibitors. Chlorpromazine is a known specific inhibitor of clathrin-mediated endocytosis,
disrupting clathrin disassembly and inhibiting receptor recycling [261, 262]. Cytochalasin
D is an inhibitor of actin polymerization to suppress micropinocytosis/phagocytosis [261,
262]. The ATP synthesis inhibitor, sodium azide (NaN3), was used as a control to inhibit
all types of endocytosis [263].
Prior to co-incubation with MOF particles and inhibitors, the safe dose of each inhibitor
was determined by MTT assay. Cells were incubated with MIL-100(Fe)-Cy5±Man and
MIL-88A(Fe)-Cy5-Man particles in the presence of endocytosis inhibitors, namely, 10
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µM chlorpromazine (CPZ), 5 µM cytochalasin D (cytoD), or 50 mM sodium azide
(NaN3). According to Fig 2.11c, the fraction of cells containing MOF particles reached
100% after 8 h in both types of MIL-100(Fe) nanoparticles. Although the internalization
of MIL-88A(Fe) particles did not reach plateau at that point, with only 12% (MIL88A(Fe)-Cy5) and 25% (MIL-88A(Fe)-Cy5-Man) of cell population, in consideration of
inhibitor toxicity 8 h incubation time was chosen for inhibitory analysis.
Several studies have shown that cellular uptake of MOFs is an energy-dependent process
[264-266]. As shown in Fig 2.14, NaN3 (metabolic inhibitor) presence resulted in a
considerable decrease in the cellular internalization with a 60% decrease relative to the
control cells in all four groups, indicating that internalization is an energy-dependent
process, consistent with the literature. There was a statistically significant reduction of
uptake by approximately 40% in cytoD-treated cells compared to the control cells. It is
noticeable that the MIL-100(Fe)-Cy5 with cytochalasin D demonstrated a much higher
fluorescent signal than the non-treated control group. This enhanced fluorescent signal
from MIL-100(Fe)-Cy5 group could be the experimental artifact. Therefore, the
internalization of MIL-100(Fe) particles in 3D4/21 cells was further observed under
microscopy. From transmitted light images (Fig 2.15), both types of MOFs in the absence
of inhibitors accumulated within cells (black arrowheads), whereas particles in the
presence of cytochalasin D stayed in extracellular space (black arrows). The images
obtained by microscopy did not support the data from flow cytometry.
Interestingly, the cells treated with chlorpromazine (clathrin-mediated endocytosis
inhibitor) showed that the uptake of non-mannosylated particles remained approximately
the same as that of the control, whereas the uptake slightly increased in mannosylated
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MOF particles. Clathrin-mediated endocytosis had no contribution to MOFs uptake in
AMs. Based on the above results, the internalization of MOF particles is predominated by
micropinocytosis/phagocytosis.

Figure 2.14 Inhibitory study of endocytic pathways of MOF particles in 3D4/21 cells.
Data are shown as means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA
followed by Dunnett test). Each measurement was carried out in quadruplicate; over
10,000 events were gated per one measurement.
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Figure 2.15 Inhibitory effect of cytochalasin D on uptake of MIL-88A(Fe)-Cy5 and
MIL-88A(Fe)-Cy5-Man in 3D4/21 cells. A large number of particles accumulated in
extracellular space with pretreated cytochalasin D for 30 min (Black arrows).
2.3.6 Intracellular colocalization
To investigate the fate of the endocytosed MOF particles, 3D4/21 cells were incubated
with MIL-88A(Fe)-Cy5-Man or MIL-100(Fe)-Cy5-Man particles for 5 h and then stained
with a lysosome marker (LysoTracker Green DND-26 dye). As shown in Fig 2.16, the
colocalization between particles and LysoTracker was observed at perinuclear region
(Mander’s coefficients between Cy5/LysoTracker channels were 0.68 ± 0.12 and 0.81 ±
0.08 for MIL-88A(Fe)-Cy5-Man and MIL-100(Fe)-Cy5-Man, respectively), represented
by yellow color in merged images (white arrows). After endocytosis, the vesicles
containing particles will progressively acidify. The high level of colocalization of
mannosylated MIL-100(Fe) and MIL-88A(Fe) with acidic organelles indicates MOFs
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were prone to accumulate in acidic compartments (such as early endosomes, phagosomes,
and phagolysosomes) after entering macrophages. There was no significant difference
between these types of MOFs. Degradation in acidic compartments is undesirable for
most drug delivery systems, and many MOF-based delivery systems are designed to
escape lysosomes to prevent the premature release of cargos [267] or acidic degradation
of MOF structures [265, 266, 268]. These MOF properties may be advantageous in
infectious disease applications since a large number of intracellular pathogens have been
found to reside in the acidic niche via diverse mechanisms [269, 270].

Figure 2.16 Intracellular localization of fluorescent, mannosylated MIL-88A(Fe) and
MIL-100(Fe) nanoparticles in 3D4/21 cells. Incubation of cells with mannosylated Cy5labeled MOFs (red) after 5 hours resulted in their accumulation (white arrows) in acidic
compartments stained with LysoTracker Green (green). Staining with Hoechst 33342
determines nuclei of 3D4/21 cells (blue). Scale bars are 10 µm.
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2.4 Conclusions
In this chapter, fluorescently labeled carboxylate MIL-88A(Fe) and MIL-100(Fe)
particles were successfully synthesized and modified with mannose via amine-carboxylic
acid coupling reaction to study their potential in applications as “pathogen-like” particle
drug delivery systems for infectious diseases. The internalization kinetics, endocytosis
pathway, and intracellular fate of mannosylated and non-mannosylated MOFs were
conducted in 3D4/21 swine alveolar macrophages. The data show that MIL-100(Fe)
nanoparticles were internalized faster and higher compared to MIL-88A(Fe)
microparticles. However, the mannosylation did not increase MIL-100(Fe) cellular
uptake further. By contrast, rod-shaped MIL-88A(Fe) particles exhibited a slower kinetic
profile and less cellular uptake, likely due to its micro-scale size, but uptake was
increased significantly with mannosylation. Micropinocytosis/phagocytosis was the
major endocytic pathway involved in MOF particle uptake. Endocytosed particles
accumulate in acidic compartments where many pathogens are known to reside and
survive, indicating the opportunity to deliver therapeutic agents in the pathogen proximity.
Cellular uptake highly depends on the size, shape, and surface functionality of particles.
The choice of particles with different physicochemical properties needs to be based on
biological application.
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Chapter 3 Development of M.tb mimicking MIL-88A(Fe) for TB
3.1 Introduction
Currently, the effective treatment for TB is a 6-month regimen of 4 first-line antibiotics.
For people with drug-susceptible TB, this treatment had a success rate of at least 85%, as
reported by WHO[2]. However, the lengthy duration of treatment, improper use, and poor
patient compliance has led to drug-resistant M.tb strains. Multidrug-resistant TB (MDRTB) remains a public health threat. It is estimated that half a million new cases have
resistance to the most effective first-line antibiotic, 78% resistant to multiple
antibiotics[2]. The treatment of MDR-TB requires a longer time and more complicated
drugs, which are more expensive and less effective. The treatment success rate for MDRTB was 57% globally[2]. Therefore, improved therapeutic approaches are highly needed
to avoid drug resistance.
The host-directed therapy (HDT) is a new and emerging approach in TB treatment, which
is intended to directly enhance the host’s innate response to TB infection rather than
targeting the bacterium itself. The potential HDT strategies against M.tb include targeting
granuloma structure, inducing macrophage autophagy, optimizing inflammatory response,
modulation of immune function, or enhancing the cell-mediated immune response[271].
The current HDT has focused on using repurposed drugs to improve the treatment
outcomes of drug-resistant TB. Metformin (MET) is a well-known drug for type 2
diabetes. Many clinical studies have reported the potential role of MET as an adjuvant
agent against TB with promising outcomes, such as less pulmonary cavitation, protection
against reactivation of latent infection to active diseases, decreased mortality, and
relapse[108, 272-274].
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Biomimetic microparticles that mimic M.tb may enhance recognition and uptake by
alveolar macrophages. These particles could have similar cellular trafficking as M.tb,
further modulating host responses to promote bacteria killing. The use of a biomimetic
microparticle host-directed therapy to target the infected cells could be effective against
M.tb infection and overcome the emergence of drug resistance. Bacterial- and viralderived biomimetic particles have been widely used in cancer, vaccines, and
immunotherapies[171, 275-278]. Those particles can be pathogen responsive and hostdirected, which improves therapeutic efficacy. However, biomimetic approaches are
relatively unexplored for TB treatment. This chapter aims to develop biomimetic particles
as HDT drug delivery systems for TB. MOFs as anti-TB drug delivery systems have
been reported in Fe-based[141, 279], Zn-based[143], and Cu-based MOFs[144], but none
of them was a biomimetic delivery system.
The MIL-88A(Fe) was selected to use in biomimetic microparticles HDT approach for
TB due to their non-toxic components (fumaric acid and Fe (III)), similar size and shape
as M.tb, and surface carboxylic acid amiable to conjugation. MOFs were coated with
lipids, including mycolic acids (MAs), a predominant M.tb cell wall component. MAs are
long 2-alkyl 3-hydroxyl fatty acids, typically 60-90 carbon atoms in length. MAs, known
to be potent immunomodulators, are critical for the virulence of M.tb[280]. The M.tb
lipid -MAs were incorporated into the surface lipid coating of MIL-88A(Fe) to mimic the
cell membrane of M.tb. The M.tb-mimetic particles are expected to have alveolar
macrophage specificity. These novel microparticles that were used as the M.tb-mimicking
drug delivery system to target macrophages may create a more effective localized
treatment that can prevent or reduce drug-resistance TB.
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3.2 Materials and methods
3.2.1 Cell culture
3D4/21 swine alveolar macrophages (ATCC, CRL-2843) were cultured in RPMI 1640
medium containing 2 mM L-glutamine and supplemented with 10 mM HEPES, 1.0 mM
sodium pyruvate (Gibco), 1% PenStrep, 90% 0.1 mM nonessential amino acids (Gibco),
and 10% fetal bovine serum (FBS; Corning). A549 human lung carcinoma cells
(ATCC, CCL-185) were cultured in DMEM/F12 growth medium (Corning)
supplemented with 10 % FBS. Cells were grown in a humidified atmosphere of 5%
CO2 at 37°С.
3.2.2 Synthesis of MIL-88A(Fe)
MIL-88A(Fe) was prepared using the same method as described in Chapter 2, Section
2.2.1.2. All studies in this chapter were conducted using the new batch of MIL-88A(Fe).
3.2.3 Characterization of MIL-88A
The new batch of MIL-88A(Fe) was characterized by the following methods as described
previously in Section 2.2.2:
•

Fourier Transform Infrared Spectroscopy (FT-IR)

•

Thermogravimetric analysis (TGA)

•

Dynamic Light Scatting (DLS)

•

Scanning Electron Microscopy (SEM)

3.2.3.1 Stability
Extracellular stability:
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The stability of MIL-88A(Fe) particles was investigated in different biological media by
assessing the disassociated iron using a colorimetric method[281]. MIL-88A(Fe) particles
were added to PBS, RPMI 1640 medium (containing 2 mM L-glutamine and
supplemented with 10 mM HEPES, 1.0 mM sodium pyruvate, 90% 0.1 mM nonessential
amino acids, and 10% fetal bovine serum), and Middlebrook 7H9 medium with 10%
OADC to achieve 1 mg∙mL-1. After incubated with biological media for 2h,6h,12h, 24h,
3 days, and 7 days, samples were centrifuged at 20,000×g for 20 min. 10 µL of
supernatant from each sample was taken for iron detection.
Intracellular stability:
The sample preparation method was based on previously published protocol[282].
3D4/21 cells and A549 cells were seeded in 24-well plates at a density of 100 000 cells
per well 48 h prior to the addition of MOFs. MIL88A(Fe) particles were added to the
cells at a final concentration of 10 μg∙mL–1. After incubation for 8, 18, and 24 h, cell
medium from each well was collected in 2 mL microcentrifuge tubes. Then cells were
lysed by 0.5% Triton X-100 in deionized water, and lysates were transferred to the
corresponding microcentrifuge tubes with medium from the same well. The samples were
centrifuged at 20 000g for 10 min to remove free soluble iron or iron bound with soluble
proteins. The pellet was washed twice with deionized water and collected each time by
centrifugation. After the last washing and removing of supernatant, 100 μL of 100 mM
sodium citrate (pH 5.5) was added into each tube to destroy MOFs. Samples were
centrifuged again to precipitate the cell debris. As for 0h time point sample (consider as
100% MOF-associated iron), 10 μg∙mL–1 MOF particles were added into 1mL cell
medium followed by centrifugation and three times washing. This step is to eliminate the
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impact of particle loss during the sample preparation. Without the same treatment for the
0 h sample, the degradation might be overestimated.
In a well of 96-well plate, 10 μL of a sample (or standard) was mixed with 75 μL of 1 M
acetic buffer (pH 4.5) with 120 mM of thiourea (Sigma, St. Louis, MO), and 25 μL of a
solution containing 240 mM ascorbic acid (ACROS Organics, NJ), 3 mM Ferene S
(Sigma, St. Louis, MO), and 120 mM of thiourea. Iron (III) chloride hexahydrate (Fisher)
was used as standard. The concentration of 0.01,0.025,0.05,0.075,0.1,0.5,1,2 mM per
well were prepared for calibration plot. The optical density measurement at 595 nm was
performed using Synergy H4 Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT)
after 1 h upon mixing the reagents.
3.2.4 Development of lipid-coated MIL-88A(Fe)
3.2.4.1 DPGG modification of MIL-88A(Fe)
The surface modification of MIL-88A(Fe) particles was based on coordination with
phenolic lipid by a phase transfer process[283]. Briefly, MOF particles were dispersed in
water (1 mg∙mL-1) and then added to a CHCl3 solution of 1,2-dipalmitoyl-sn-glycero-3galloyl (DPGG; 1mg∙mL-1; Avanti Polar Lipids). After stirring the suspension for 30 min,
ethanol was added to break the emulsion. Finally, the DPGG-modified MIL-88A(Fe)
particles were collected by centrifugation and washed with ethanol three times.
3.2.4.2 Mycolic acid on DPGG-modified MIL-88A(Fe)
Due to mycolic acid (MA) high cost, it was omitted from the lipid coating optimization
process. MA was only added into the formulation until the ideal coating was achieved.
DPGG- modified MIL-88A(Fe) particles were coated with phosphocholine (PC) and
cholesterol(Chol) using the solvent-spherule evaporation method with modification[284].
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In brief, 1 mL of a 0.15 M sucrose solution was mixed with 1 mL of chloroform
containing PC and Chol (3:2 molar ration; 10µ mol total lipid) and 1-2 mg of DPGGMIL-88A(Fe) by vertexing for 1 min. For mycolic acid-DPGG-MIL-88A(Fe), 5% and 10%
of total lipids were substituted with mycolic acid (Sigma). Next, 0.5 mL of diethyl ether
containing the same lipids as above was mixed with 2.5 mL of a 0.2 M sucrose solution.
The resulting water-in-chloroform emulsion was mixed with diethyl ether-in-water
emulsion by vertexing for 1 min and then added into the round bottom flask linked to the
rotary evaporator. The organic solvents were evaporated under vacuum evaporation for
2h at the temperature of 55 °С. The bilayer lipid coated particles were centrifuged twice
with water at 600 g for 10 min. To separate the coated from non-coated MIL-88A(Fe),
discontinuous sucrose density gradient centrifugation was used. The sucrose column was
prepared by adding 60% and 120% sucrose in an ultracentrifuge tube (Beckman). 1mL
mixture was placed on the top of the gradient and then centrifuged for 1 h at 20,000 g in
an ultracentrifuge. Free lipids remained on the top. The sample was then washed with
water 3 times to remove sucrose.
3.2.5 Characterization of lipid-coated MIL-88A(Fe)
3.2.5.1 Zeta-potential measurements
The zeta-potentials of MIL-88A(Fe) and lipid-coated MIL-88A(Fe) were determined
using Zetasizer, Nano-ZS (Malvern). Before analysis, particles were suspended in
distilled water at 50µg∙mL-1 and sonicated under ultrasound for 10 min. All analyses
were carried out in triplicate.
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3.2.5.2 Transmission electron microscope (TEM)
The morphology of samples was characterized using a JEM-2100Plus transmission
electron microscope (JEOL, Japan) operating at an accelerating voltage of 200 kV.
Particles dispersed in water were deposited on a 200-mesh copper grid with carbon film
(Electron Microscopy Science) and dried in air. Images were taken by Gatan 832 CCD
camera.
3.2.5.3 Energy-dispersive X-ray spectroscopy (EDX)
The samples' chemical characterization and elementary analysis were investigated using a
scanning transmission electron microscope equipped with an energy-dispersive X-ray
spectroscopy (EDX) detector (X-MaxN, Oxford Instruments) at an accelerating voltage of
200 Kv.
3.2.5.4 TGA
Thermogravimetric measurements were performed on a thermogravimetric analyzer
(Perkin Elmer Diamond TGA/DTA STA 6000). 2-3 mg samples were heated from room
temperature to 500 °C with an oxygen flow of 200 ml/min.
3.2.5.5 Cytotoxicity study
Cytotoxicity of lipid-coated MIL-88A(Fe) was evaluated by MTT assay. 3D4/21 cells
were seeded on 96-well plates at an initial density of 5000 cells/well and cultured
overnight. Cells were treated with varying concentrations (1,10, 25, 50,100,250, and 500
µg∙mL-1) of lipid-coated MIL-88A(Fe) particles for 24 h to determine the cytotoxicity.
(MTT-assay, see chapter two, section 2.2.6)
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3.2.6 Metformin loaded MIL-88A(Fe)
3.2.6.1 Solubility of metformin
To identify the solvent in which metformin hydrochloride (MP Biomedicals) was the
least soluble for maximum precipitation yield, 5 mg drug was dissolved in the following
solvents (500 µL): DMSO, tetrahydrofuran (THF), acetonitrile (ACN), acetone,
dimethylformamide (DMF), methanol, isopropanol (IPA), propanol. The solubility was
determined by HPLC.
3.2.6.2 Encapsulation method
Metformin and MIL-88A(Fe) were dispersed in 1mL ethanol followed by stirring for 12
h. Next, the mixture was added into 15 mL organic solvent (with lowest metformin
solubility) dropwise under constant stirring speed (500 rpm) at room temperature. The
sample was collected by centrifugation at 20,000×g for 10 min. Prior to lyophilization,
the sample was quickly washed with water to remove the free drug absorbed on the
surface of particles. To determine the drug loading, metformin encapsulated MOF
particles were destroyed by incubation in 100 mM citrate buffer (pH 5.5) at 40°C for 24 h
to release all the drugs.
3.2.6.3 Quantification of metformin by high-performance liquid chromatography
(HPLC)
Quantification of encapsulated metformin was performed by HPLC (Agilent Technology
1220 Infinity LC, Germany) coupled with a UV Detector and software. The analysis was
carried out on a reversed-phase C18 column (250nm × 4.6mm, 5.0µm) using a mobile
phase consisted of acetonitrile-aqueous phase (20 mM K2HPO4, adjusted to pH 2.8 using
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H3PO4) (10:90, v/v) at the UV detection of 232 nm. The flow rate was 1mL∙min-1, and the
injection volume was 20 µL.
Metformin hydrochloride (Met∙HCL; salt form) stock solution of 1000 µg∙ mL-1 was
made in triplicate. The standard solutions of 50,25,20,15,10,5,1 µg∙ mL-1 were diluted
from the stock using water. The calculated concentration of the metformin (Met; free
base) was obtained by the following equation:
Concentration (Met)= Concentration (Met∙HCL) × Conversion factor (F)
F=
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Equation 3.1
3.2.7 Bacteria culture
3.2.7.1 Bacteria strain and growth condition
Mycobacterium. Avium subsp. avium (ATCC,25291) was cultured in Middlebrook 7H9
medium (Sigma-Aldrich,) supplemented with 10%(v/v) OADC (oleic acid, albumin,
dextrose, catalase; Sigma-Aldrich,) and 0.5% glycerol(v/v) at 37 °C with 5% CO2.
Bacteria were grown for 2 weeks until OD600nm reached the log phase. To make
bacterial stock, 500µL of bacterial suspension was dispensed into a 2 mL cryovial, and
500µL of 50% glycerol was added.
3.2.7.2 Growth profile
A 100 µL aliquot of bacterial stock was inoculated in 10 mL of Middlebrook 7H9
medium with 10% OADC. The bacterial culture was incubated in constant shaking at
200rpm to avoid clump formation. The optical density (OD600) of 1mL bacterial
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suspension was measured every day for 21 days using Bio-photometer (Eppendorf). The
bacterial suspension was streak onto an M7H10 OADC media agar plate to determine the
colony-forming units per mL by serial dilution.
3.2.7.3 Acid fast staining (Ziehl Neelsen)
One colony of M.avium was mixed with one drop of water and smeared onto a slide.
After air drying, the slide was placed on a hot plate to fix the bacteria. 1% carbol-fuchsin
dye was added, and the slide was left on a hot plate for 5 min. The slide was rinsed with
water until the solution became clear and then washed with 1% acid alcohol for 20 sec.
After rinsing again with water, 0.1% methylene blue (counterstain) was added for 1 min.
The slide was rinsed with water and left to air dry before checking under a microscope.
3.2.8 M.avium lipid extraction and analysis
3.2.8.1 Method
Mycolic acid extraction is based on a procedure described by Butler and Kilburn[285].
Briefly, bacteria were harvested by centrifugation at 2000 g for 20 min. 2 mL of
saponification reagent (25% KOH in 50% ethanol) was added to the bacteria pellet.
Saponification of bacteria was performed by autoclaving for 1 h at 121°C. 50% HCL was
added to acidified when the temperature cooled to room temperature. The mycolic acids
were extracted by adding 2 mL chloroform and vigorously shaking. Then the mixture was
centrifugated for 5 min to assist separation of the chloroform layer. Finally, the lower
organic layer was collected and evaporated to dryness.
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3.2.8.2 Thin-layer chromatography (TLC)
TLC was performed using silica gel 60 F254 TLC aluminum sheets (Merck). The mobile
phase was 100% chloroform. TLC chamber was filled with the mobile phase to 1
centimeter of the bottom, saturating the tank for 15 min.
3.2.8.3 Fourier Transform Infrared Spectroscopy (FT-IR)
The chemical structures of mycolic acid standard (from Mycobacterium tuberculosis
(bovine strain); Sigma-Aldrich) and extracted lipids were characterized by Nicolet 380
FT-IR spectrometer (Thermo Scientific Corporation). The sample was placed on a
diamond crystal plate at room temperature. Each spectrum was scanned in the spectral
region of 4000–500 cm−1.
3.2.9 M.avium fluorescent labeling
3.2.9.1 Method
Biorthogonal ligation with alkyne-functionalized dye was used to label the azidemodified trehalose analogs of glycolipids of M.avium[286]. 1 mL frozen bacteria stock
was inoculated into 50 mL Middlebrook 7H9 medium with OADC and 5% glycerol. The
culture was incubated at 37°С with shaking until reaching the log phase and diluted to the
desired density (OD600~0.5) to start the experiment. Bacteria were seeded in a 96-well
plate. Next, 6-azide-trehalose (TreAZ; Click Chemistry Tools) was added at a final
concentration of 25,50,100 or 250µM at a volume of 200 µL. To prevent evaporation and
clumping during the incubation period, 200 µL of water was added to all outer-perimeter
wells of 96-well plate, and each well was resuspended every 24h. The plate was
incubated for 3-5 days until OD600 reached ~0.8-1.0. Next, the plate was centrifuged and
washed three times with PBSB (PBS 1X with 0.5 % bovine serum albumin). Next, cells
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were incubated with alkyne-functionalized Alexa Fluor 488(Click Chemistry Tools; 1:1000
dilution of 1 mM stock solution in DMSO into PBSB; volume 150 μL) for 30 min. After the
incubation period, bacteria were centrifugated at 4 °C and washed with PBSB three times.

Next, bacteria were fixed with 200 µL of 4% paraformaldehyde in PBS for 1h, followed
by final washing with PBS two times. Samples were readied for analysis by flow cytometry
and microscopy.

4.2.9.2 Flow cytometry
The fluorescence intensity of bacteria treated with different concentrations of TreAZ was
measured by flow cytometry. Flow cytometry was conducted on a BD Accuri™ C6 Plus

flow cytometer (BD Biosciences) equipped with a 488-nm argon laser. 100,000 cells were
collected for each sample, and samples were prepared in quadruplicate. The fluorescence

data were processed using FlowJo v10.7.1
4.2.9.3 Fluorescence microscopy
Bacteria were air-dried and mounted on a slide with a coverslip. Microscopy was
performed on a BZ-X800 All-in-One fluorescence microscope equipped with a × 60/1.4
NA Plan-Apochromat oil immersion objective lens, and the channel imaged were brightfield and GFP.
3.2.10 MIL-88A(Fe) on the impact on M.avium growth
M.avium was cultivated in the flask with gentle agitation until an OD600 of ~0.5 was
obtained. Bacteria suspension was adjusted to have an OD600 of 0.02. 100µL of bacterial
dilution was added to each well of a 96-well plate. MIL-88A(Fe) and FeCl3∙6H2O were
dispersed in water and added into each well with finial concentrations of 1, 10, and
100µg∙mL-1. The plate was incubated at 37°С for 24h and 72h. Bacteria from three
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parallel wells of each concentration at specified time points and appropriate serial 10-fold
dilutions were seeded on Middlebrook 7H10 agar plates. The plates were incubated for
two weeks.
3.2.11 Cell uptake
3.2.11.1 cell uptake kinetics in non-infected macrophages
3D4/21 cells were seeded in 24-well plates at a density of 6 × 104 cells/well and cultured
for 48 h. 1) MIL-88A(Fe)-Cy5(12 μg∙ mL−1) and lipid-coated MIL-88A(Fe)-Cy5(50
μg∙ mL−1); 2) lipid-, 5% MA-, 10% MA-, 5% extracted lipid- MIL-88A(Fe)-Cy5 particles
(20 μg ∙mL−1), were added into 3D4/21 cells. After incubation of MOFs for 2 h, 5 h, 8 h,
12 h, and 18 h, the growth medium was removed, and cells were washed with HBSS.
Cells were dispersed with 75 μL per well of 0.25% trypsin in 37°С incubator for 15 min,
suspended in 500 μL Versene solution per well and collected in 2.0 mL microcentrifuge
tubes. Following centrifugation at 500×g for 30 s, cells were resuspended in 300 μL of
Versene solution containing 1 μg mL−1 propidium iodide to differentiate live and dead
cells. The intensity of nanoparticles internalized by cells was measured using a BD
Accuri™ C6 Plus flow cytometer (BD Biosciences) equipped with a 640 laser in 625675 nm channel. Over 10,000 events were gated per sample. Samples were prepared in
quadruplicate.
3.2.11.2 Mechanism of endocytosis pathway
3D4/21 cells were seeded in 24-well plates at a density of 6 × 104 cells/well and cultured
for 48 h. Cells were pretreated with 5 μM cytochalasin D, 1 μM filipin III, 10 μM
chlorpromazine, or 50 mM sodium azide for 30 min prior to the addition of MOF
particles. After incubation of MOFs for 8 h, the growth medium was removed, and cells
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were washed with HBSS. Sample preparation, flow cytometry, and data collection
followed the same procedure as described in Section 3.2.11.1.

3.3 Results and discussion
3.3.1 Synthesis and characterization of MIL-88A(Fe)
The new batch MIL-88A(Fe) particles were successfully synthesized and characterized
by dynamic light scattering (DLS), infrared spectroscopy (IR), thermogravimetric
analysis (TGA), and scanning electron microscopy (SEM) using Zetasizer, Nano-ZS
(Malvern), Fourier-transform infrared spectrometer (Nicolet iS50), Perkin Elmer
Diamond TGA/DTA STA6000 thermogravimetric analyzer and JEOL JSM-7100F
microscope. Figure 3.1 depicts the FTIR spectrum of MIL-88A(Fe) and its linker,
fumaric acid. The bands at 1390 cm-1and 1601 cm-1 in MIL-88A(Fe) can be attributed to
the symmetric and asymmetric vibration of the carboxyl group, respectively, indicating
the successful coordination of iron ions and fumaric acid. The TGA analysis was shown
in Fig 3.2. Two-stage weight loss was observed: the first stage (<100 °С) can be
attributed to water loss. The second weight loss was between 250 °С to 350 °С,
indicating the decomposition of the MOFs. SEM images show that the obtained MIL88A(Fe) particles have spindle-shaped with a diameter of 0.6±0.1µm and length of
2.6±0.2 µm (Fig 3.3). The zeta potential of MIL-88A(Fe) was 22.1±3.36 mV (Fig 3.4).
All the physicochemical characterization confirms the success of synthesizing MIL88A(Fe) particles congruent with characteristics of previous batches.
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Figure 3.1 FT-IR spectrum of MIL-88A(Fe) and fumaric acid.

Figure 3.2 The TGA curve of MIL-88A(Fe).
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Figure 3.3 The SEM images of MIL-88A(Fe) under the magnifications of (a)5k x; (b)15k
x;(c)35k x.
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Figure 3.4 The zeta potential distribution of MIL-88A (Fe).
The extracellular stability of MIL-88A(Fe) was carried out in 3 different biological media,
namely PBS, 3D4/21 cell medium, and bacteria medium for mycobacteria, for different
periods. The protocol developed in our lab enables the complete elimination of soluble
and protein-associated iron[282]. Therefore, only the MOF-associated iron (not degraded
fraction) was measured by the colorimetric assay. As shown in Fig 3.5, MIL-88A(Fe)
was very stable in PBS for up to a week. However, MIL-88A(Fe) started to degrade after
72 h in cell medium with about a 15% decrease of MIL-88A(Fe)-associated iron at the
end of the incubation period. The rate of MIL-88A(Fe) degradation was much higher in
the bacteria medium. 30% of MOF-associated iron was detected within 6 h, and nearly
half of the particles degraded after a week. Bacterial medium-7H9 broth contains sodium
citrate and ferric ammonium citrate. 100 mM sodium citrate was used for the
decomposition of MOF[282]. The citrate ions, which have a more robust interaction with
Fe3+ compared to fumaric acid, substituted the linkers, leading to the decomposition of
MIL-88A(Fe). The intracellular stability of MIL-88A(Fe) was conducted in both 3D4/21
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alveolar macrophages and A549 alveolar basal epithelial cells. The degradation kinetics
in Fig 3.6 shows MIL-88A(Fe) particles had an initial degradation of 17% within 8h,
followed by a slight decomposition in the following 10 h. Then they remained relatively
stable until 24h post-exposure to 3D4/21 cells. In A549 cells, particles experienced a
gradual degradation trend with nearly 40% the particles degraded after 24 h incubation.
Slower degradation in macrophages compared to epithelial cells leads to more prolonged
exposure of particles to targeted macrophages, indicating the potential use of MIL88A(Fe) in controlled released drug delivery for intramacrophagic infection diseases.
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Figure 3.5 The degradation profile of MIL-88A(Fe) in PBS, cell medium, and bacteria
medium at different time points. Data are shown as mean ± SEM. Each measurement was
carried out in triplicate.
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Figure 3.6 Intracellular degradation of MIL-88A(Fe) in 3D4/21cells and A549 cells at
different time points. Data are shown as mean ± SEM. Each measurement was carried out
in a quadruplicate.
3.3.2 Development and characterization of lipid-coated MIL-88A
Lipid-coated MIL-88A(Fe) particles have been reported previously as a drug delivery
system in chemotherapy[287, 288]. The lipid coating act as a temporary shell for
encapsulated drugs, allowing efficient drug loading and control of release. Wuttke et al.
reported that MOF nanoparticles, MIL-88A(Fe) and MIL-101(Cr), can efficiently load
with dye molecules while the lipid bilayers coated on MOFs prevent their premature
release[289]. Ploetz et al. showed that the lipid coating on MIL-100(Fe) nanoparticles
controlled iron delivery to induce pyroptosis in cancer cells[290]. However, there is little
study about using lipid-coated MOF for biomimetic applications.
Studies above used a controlled solvent exchange method to deposit the lipid onto the
MOF surface[291]. Briefly, lipids and MOFs are dispersed in a solvent that is completely
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miscible with water, such as ethanol and isopropanol. Thus, as water content drastically
increases, lipids that are not soluble in water start to adhere to the surface of the particles.
However, this widely used method is not applicable in our case. First, mycolic acid,
which contains between 60 and 90 carbon atoms, is very hydrophobic. It can dissolve in
chloroform, but chloroform is immiscible with water. Second, MIL-88A(Fe) size in those
studies was about 100 nm, much smaller than the one we used (3 µm in length). Zhu et al.
described a novel strategy for providing MOFs with versatile surface functionalization
through direct metal coordination with a phenolic lipid using a phase transfer process(Fig
3.7b)[283]. The galloyl head group of phenolic lipids, DPGG (Fig 3.7a), has substantial
interaction with the activated metal-binding sites of the surface on MOFs, allowing rapid
lipid coating without disrupting the integrity of MOF structure. In MIL-88A(Fe) structure,
there are three binding sites between Fe (III) and phenol groups, resulting in mono-, bis-,
and tris-complex.
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Figure 3.7 (a) Chemical structure of DPGG lipid; (b) Scheme of the surface
functionalization of MOF particles by a phase transfer reaction. Adapted from reference
[283].

The next step is to fuse a second functional layer onto DPGG-modified MOF cores to
form a MOF-supported hybrid bilayer. As the solvent exchange deposition method is not
suitable in our case, the thin-film hydration method for the preparation of liposomes was
utilized experimentally. Mycolic acid was not included in the trials due to the high cost.
First, DPGG-MOFs, phosphatidylcholines (PC), and cholesterol (Chol) were thoroughly
mixed in the chloroform. Next, the organic solvent was evaporated to form a thin film
using a rotary evaporator, followed by hydration to form hybrid liposomes. However, by
vigorous agitating, the thin lipid film was still hardly suspended in the aqueous medium.
After extensive bath sonication, hydrated lipid suspension was formed. Figure 3.8 shows
that the mixed MOF-lipids suspension had a broad range of size distribution. The first
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part could be excessive lipids vesicles(I), while the second part might be lipid-coated
MOFs.

Figure 3.8 Size distribution of MOF-lipid suspension using a hydration thin film.

Antimisiaris et al. described using giant liposomes (~5.5 m) as vaccines carriers to
incorporate particulate antigen, Mycobacterium Bovis bacillus CalmetteGuérin (BCG)[284]. Since MIL-88A(Fe) particles exhibit a similar size and shape as
bacilli, the strategy of formulating the bacteria-containing liposomes with minor
modification could be applied to develop the lipid-coated bacteria-mimicking MOFs. The
first trial followed the methodology described in Antimisiaris et al. paper. In brief, 1mL
of a 0.15M sucrose solution containing MIL-88A(Fe) was mixed with 1mL chloroform
containing PC and Chol. This water in chloroform emulsion was remixed with diethyl
ether in water emulsion prepared from 0.5 mL diethyl ether containing the same lipids
mixed with a 2.5mL of 0.2M sucrose solution. The emulsion was placed in a shaking
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incubator at 37°C with flushing nitrogen to evaporate organic solvent. Generated
liposomes were centrifuged twice over 5% glucose solution, collected, resuspended in
water for TEM analysis.

Figure 3.9 Representative TEM images of lipid-coated MIL-88A(Fe) in trial one.

We found many particles have a thin layer lipid coating like the top two images in Fig 3.9,
with zeta potential near neutral, indicating the surface coating. We also observed many
crystal structures on the surface of lipid-coated particles, which could be excessively used
sugar molecules in the preparation.
Next, instead of adding MIL-88A(Fe), DPGG-MIL-88A(Fe) was added in 1mL
chloroform containing other lipids. The same procedure was followed, but the
formulation was washed with water to remove sugar crystals. As shown in Fig 3.10, most
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particles were not covered with crystals; therefore, washing with water could help
remove crystals’ precipitation on the particles. Particles also exhibited a thicker and more
coverage lipid coating than the previous batch. Compared to pure MIL-88A(Fe), DPGGMIL-88A(Fe) has a hydrophobic shell that could facilitate the secondary lipid interaction.

Figure 3.10 Representative TEM images of lipid-coated MIL-88A(Fe) in trial two.
In the third trial, we modified the process using a rotary evaporator to remove the organic
solvent. In liposome preparation, the lipid film is formed after drying out the solvent.
Interestingly, the initial emulation became viscous and gel-like as time increased under
the rotary-evaporator, eventually turning into the aqueous solution (Fig 3.11a). To
separation of the lipid-coated MOFs from the empty lipid vesicles, sucrose gradient
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fractionation was used. The mixture was placed on the top of the gradient for
ultracentrifugation. The separation of the particles and lipid components was shown in
Fig 3.11b. The top layer (yellow arrow), purple-grey, could contain PC, DPGG, and
DPGG-Fe3+ complex. The Fe3+ ion with a phenolic group will give a violet, purple, or
red-brown color depending on the pH and ratio of Fe3+ ion to phenolic group[283]. The
resulting lipid-coated MIL-88A(Fe) particles were shown in Fig 3.12.

Figure 3.11 The transition from gel to an aqueous solution.

The TEM images confirm the presence of lipid on the MOFs particles. Bright fields
usually indicate the lipid content, whereas MOFs are in the dark fields due to high
electron density. We found that most of the particles had a relatively uniform and clear
coating. The zeta potential of lipid-coated MIL-88A(Fe) was -22.8 ± 9.59 mV. The
change in surface charge from positive to negative also indicates the successful lipid
coating. The TGA curve shows that lipid-coated particles were more stable between 20°C
to 200°C compared to bare particles and then exhibited a gradual weight loss step up to
500°C (Fig 3.13). In comparison, the bare particles started to degrade at 250°C
drastically. The potential toxicity of lipid-coated particles was evaluated on 3D4/21 cells
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using MTT assay. It is shown in Fig 3.14 that lipid-coated particles were non-toxic up to
100 μg ∙mL−1 with approximately 85% viability, which is similar to the bare particles
(See
Fig 2.1 c in Chapter two). Based on the MTT assay result, the IC50 of the lipid-coated
particles was around 500 μg ∙mL−1.

Figure 3.12 Representative TEM images of lipid-coated MIL-88A(Fe) in trial three.

98

Figure 3.13 The TGA curve of MIL-88A(Fe) and lipid-coated MIL-88A(Fe).
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Figure 3.14 MTT assay of 3D4/21 cell viability after 24 h exposure to lipid-coated MIL88A(Fe). Data are given as means±SD.
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3.3.3 Metformin loaded MIL-88A(Fe)
Metformin (MET) is the most used drug for type 2 diabetes mellitus (DM). Many groups
have reported the potential of using MET as host-directed therapy for TB[108, 274, 292].
Singhal et al. concluded that in vitro MET controlled the growth of drug-resistant M.tb by
inducing mitochondrial reactive oxygen species(ROS) and increased acidification of
phagosomes which also facilitated phagosome-lysosome fusion[108]. In their M.tb
infected mouse model, MET improved the efficacy of conventional anti-TB drugs,
reduced tissues pathology and inflammatory responses, and enhanced the host immune
responses. Lachmandas et al. investigated both in vitro and in vivo effects of metformin
in humans [293]. MET was demonstrated to ameliorate the pathological inflammatory
responses and enhance antimycobacterial activity. Degner et al. reported that MET
significantly decreased mortality among patients with or without DM during TB
treatment[274]. Many experimental and clinical studies suggest MET is a promising
candidate HDT drug for improved TB treatment outcomes. In addition, MET is a
commonly used drug and cheap, which is the advantage as most TB cases are in thirdworld counties. Therefore, MET was selected as an HDT drug for this study.
A few studies have been found using MOFs as a MET delivery system. Vahed et al.
demonstrated a novel MET-MIL-100(Fe) system in which MET was combined with Fe3+
and trimesic acid as an organic linker[294]. Particles were further loaded with MET by
incubation in the drug solution. The same group developed alginate-coated zeolitic
imidazolate MOF(ZIF-8) as a MET carrier for controlled release[295]. Sethuraman et al.
developed zinc-based MOF(ZIF-8) to load MET for pH-sensitive release for lung cancer
treatment[296].
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The Nanoprecipitation method was adapted to encapsulate MET. In brief, MIL-88A(Fe)
was incubated in MET EtOH solution overnight. Then, the suspension was added into an
organic solvent (miscible with H20) in which MET has the lowest solubility to ensure a
high drug loading. The solubility of MET in different solvents was determined by HPLC
and calculated from the standard curve in Fig 3.15. The results show that MET has the
lowest solubility in THF (practically insoluble). To determine the drug loading, METMIL-88A(Fe) particles were first destroyed, and the encapsulated drug was analyzed by
HPLC. The drug loading (DL) from those three samples was 12.78%, 12.42%, and 12.33%
(Table I). The novel MET-MIL-100(Fe) system mentioned above can reach a DL of
35%. Wang et al. reported that the DL of MET-chitosan nanoparticles was 37.3 ±
3.6%[297]. The loading capacity of MET-MIL-88A(Fe) was still considerably high
compared to alginate nanoparticles (3.12%), solid lipid nanoparticles (<1%), and
chitosan-PLGA nanoparticles (~1%) [298-300]. Although MET has shown a lot of
promising results in vitro, it is not very potent. Rodriguez-Carlos et al. showed that at
least 2mM MET could significantly reduce bacillary loads in macrophages and lung
epithelial cells[301]. Theoretically, if 100 µg∙mL-1 of particles (safe concentration
determined by MTT assay) were given to the cells, to have the same effect as 2 mM free
MET, 77.4% drug loading would be required. In our case, MET-MIL-88A(Fe) particles
would be coated with bacterial lipids, which may play a role in recognition and immune
response so that the dose of MET could be lower. Another concern is drug loss during the
lipid coating process. From TEM/EDX image (Fig 3.16), iron-based MOF was coated
with lipids(carbon). A sufficient nitrogen element was still not overlapped with carbon
shown in the element mapping of the lipid-coated particle. However, EDX is not as

101
sensitive as XPS analysis. XPS is especially sensitive to light elements such as C, N, and
O[302].
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Figure 3.15 Standard curve of MET used for HPLC method.

Table 3.1 Drug loading of MET-MIL-88A(Fe).
mg
MET-MIL-88A(Fe)
MET
DL%

I
2.38
0.3042
12.78%

II
2.45
0.3042
12.42%

III
2.34
0.2886
12.33%

50
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Figure 3.16 (a) TEM image of lipid-coated MIL-88A(Fe) particles; (b)Element mapping
of metformin-loaded particles. Fe (III) indicated in yellow, carbon in red, and nitrogen in
blue.
3.3.4 Bacterial lipid extraction and labeling
Mycobacterium avium is the non-tuberculosis mycobacterial species frequently found in
animals and humans [303]. It is also known as one of the species of M.avium
complex(MAC), which is the most common deadly pathogens in people with HIV
infection[304]. M. avium is classified into four subspecies, M. avium subsp. avium, M.
avium subsp. silvaticum, M. avium subsp. paratuberculosis, and M.
avium subsp. hominissuis.
M. avium subsp. avium (MAA) was used in this dissertation study as a surrogate for
Mycobacterium. tuberculosis (MTB). MAA and MTB are pathogens that infect and
replicate inside macrophages. They both have adapted themselves to survive in the
phagosomes that fail to fuse with lysosomes. However, MAA primarily causes a
tuberculosis-like disease in birds[305]. It can also infect domestic animals, like cattle,
swine, sheep, etc. However, it is rarely found in humans[306]. The spread of MAA is
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thought to be caused by ingestion of poultry and/or soil contaminated with MAA
excreted in the feces of sick birds[303]. MAA, which is considered a lower risk
opportunistic pathogen, can be maintained in Biosafety level 2 laboratories, whereas M.tb
requires a biosafety level 3(BSL-3)facility. M.avium is also a slow-growing and rodshaped bacterium. The morphology of M.avium colonies is rough opaque with paleyellow color and irregular shape(Fig 3.17b). The mid-log phase was between OD600
0.5~1(Fig 3.18).

Figure 3.17 (a)Acid-fast stain of M.avium; (b) M.avium colonies on 7H10 agar plate.
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Figure 3.18 The growth curve of M.avium in 7H9 medium.
Mycolic acids (MA) are long-chain 2-alkyl-branched, 3-hydroxyl fatty acids, the primary
cell wall component of M.tb, constituting approximately 40-60% by weight cell envelope.
Members of the genus mycobacterium can be characterized using acid-fast staining due
to this waxy MA layer. MA-containing bacteria can retain coloration (red; Fig 3.17a)
with carbol fuchsin, whereas the other bacteria will be decolorized and take the
counterstain. MA can either be trehalose 6,6-dimycolate (TDM; cord factor) or other
glycolipid forms. MA is also believed to play a significant role in the virulence of the
M.tb[307, 308]. It has been reported that TDM can bind to mincle receptors on
macrophages[75]. MA can be presented via CD1b molecules on dendritic cells to T-cells
which are cytotoxic and produce proinflammatory cytokines IFN- γ and TNF- α [309,
310]. Coating MA on MOFs to have bacteria-like particles may mimic certain features of
M.tb infection, especially interaction of MA with macrophages. However, the cost of
commercial MA is very high. We decided to extract lipids from the lab-cultured bacteria.
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The TLC plate shows that the extracted lipids (ELs) contain several compounds. The top
band, which was the same level as standard mycolic acid (highlighted in red box),
indicates the success of MA extraction from M.avium(Fig 3.19a). The IR spectrums of
S-AM and P-MA are presented in Fig 3.19b. The purified MA exhibited similar peaks as
the commercial one, with only 1683.7cm-1 peak missing (highlighted by yellow). This
difference could be due to the two different strains (M.tb vs M.avium). IR by itself is not
100% reliable. More studies need to be done to confirm the structure of extracted MA
further.
To visualize particles, the Cy5 dye was linked on the surface of MOFs. However, during
the coating process, the outer layer of MOFs may disassociate from the framework. The
purple color on the top in Fig 3.11b indicates the existence of the Fe3+- phenolic group
complex. Meanwhile, the dyes which were conjugated with the linkers may also be lost.
Therefore, instead of fluorescent label the MOFs, we labeled the cell-surface glycolipids
of bacteria which can be extracted and coated on the particles later. M.avium was treated
with azide-modified trehalose (TreAZ). Trehalose is present as a free disaccharide in the
cytoplasm. It combines with MA to form trehalose monomycolate (TMM), which is the
precursor to trehalose dimycolate (TDM) TMM, translocated across the plasma
membrane, bound to another molecule mycolate to become TDM. Those trehalosecontaining glycolipids reside in the outer membrane, which then was tagged by alkynefunctionalized dye(alk-AF488). Analysis by flow cytometry indicates that TreAZ was
labeled on M.avium, and fluorescent intensity increased as TreAZ concentrations
increased(Fig 3.20). Even the lowest concentration, 25 µM, was sufficient and
significantly higher than the control group. Fluorescence microscopy was used to
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visualize TreAZ M.avium. Bacteria were fixed and reacted with alk-AF488. In Fig 3.21,
fluorescence was observed uniformly throughout the bacterial population. Therefore, we
can potentially form alkyne functionalized fluorescent lipid-coated particles by extracting
those TreAZ-labeled glycolipids and introducing them in the lipid layer.

Figure 3.19 (a)TLC profile of extracted lipids from M.avium. (b) FT-IR spectrum of MA
and P-MA. S-MA: standard mycolic acid from M.tb(bovine strain; Sigma-Aldrich); PAM: purified mycolic acid from M.avium; Els: extracted lipids from M.avium.
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Figure 3.20 Flow cytometry analysis of different concentrations of TreAz-labeled M.
avium (a) Fluorescence intensity of the labeled-M. avium distributions; (b) Quantified
mean fluorescence intensity.

Figure 3.21 Fluorescence microscopy of TreAz-labeled M. avium reacted with alkAF488; Scale bars, 5 µm.
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3.3.4 Impact of MIL-88A(Fe) on M. avium growth
Iron is an essential nutrient for nearly all organisms. It is a cofactor for many enzymes of
important metabolic functions. M.tb has evolved strategies to compete for iron in the host
and establish an infection. M.tb secretes siderophores with a high affinity for iron (III)
can take iron from the host proteins. It has been shown that excessive iron load could
enhance the growth of M.tb in the mouse model and the risk of active TB in humans.[311,
312]. On the other hand, iron is a key component of the Fenton reaction, generating ROS
that can kill the bacteria[313]. Ameral et al. described the regulated necrosis in M.tb
infection as ferroptosis triggered by iron overload[314]. Excessive iron induces lipid
peroxidation, resulting in plasma membrane disruption. The Gpx4 enzyme can generally
remove those lipid peroxides. However, the overloaded iron can inhibit Gpx4 expression
and/or activity.
The impact of iron-based MOFs with different concentrations on the bacteria growth was
investigated using a colony-forming assay. Treated with MIL-88A(Fe), MIL-100(Fe),
and FeCl3 for 1 and 3 days, M.avium was then plated on the 7H10 agar plate in the
incubator at 37°С. FeCl3 was used to provide free iron. Also, both MIL-88A(Fe) and
MIL-100(Fe) were made of FeCl3 and their corresponding linkers. The results are shown
in Fig 3.22. For the short exposure, the colony numbers of MOF treated groups were not
significantly higher or lower than that of the control. Interestingly, a higher number of
colonies was observed in the medium concentration FeCl3 treatment (highlighted by
yellow), whereas the high and low concentrations did not show much difference. It seems
that a specific concentration of iron is favorable for bacterial growth. In three-day
incubation, low- and medium concentrations of MOF had comparable colony number as
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the control. The high MOF concentration treated groups had more colonies than the
control but varied in each group as SD were considerably high. This is likely due to the
increased free iron from MOF degradation. Based on the results in Fig 3.5, about 20% of
MIL-88A(Fe) degraded after three days. However, FeCl3 experienced a decreased trend
in colony number as concentration increased, starting from much higher colonies to
slightly shorter than the control group. Both iron concentration and exposure time play a
role in bacteria growth. Although iron-based MOFs did not show any intrinsic
antimycobacterial activity, they still have the potential to deliver TB treatment as no
significant increase in bacteria growth using MOFs. The lipid coating may retard the
dissociation of iron from MOFs.

Figure 3.22 The number of colony-forming units of M.avium with different treatment.
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3.3.5 Effects of the coating on macrophage uptake
In chapter two, the inhibition study showed that the major endocytic pathway of MIL88A(Fe)-Cy5 internalized by alveolar macrophages was phagocytosis. The same
experiment was conducted on lipid-coated MIL-88A(Fe)-Cy5 particles to investigate if
the coating would impact the endocytosis mechanism. Cells were pretreated with
chlorpromazine (clathrin-dependent inhibitor), filipin III (caveolae-dependent inhibitor),
cytochalasin D (phagocytosis inhibitor), and sodium azide (ATPase inhibitor) prior to
incubation with MOF particles. Flow cytometry was used to quantify the number of
MOFs being internalized in macrophages. As shown in Fig 3.23, a significant decrease of
uptake was showed in the groups treated with sodium azide and cytochalasin D. This
suggests that energy-dependent endocytosis-phagocytosis is the main uptake pathway of
lipid-coated MOFs. The lipid coating did not change the mechanism of macrophage
uptake.
To compare the uptake of non-coated and coated MOFs, the amount of MOF particles
expressing the same fluorescent signal (MIL-88A(Fe)-Cy5(12 μg∙ mL−1) and lipid-coated
MIL-88A(Fe)-Cy5(50 μg∙ mL−1)) were given to cells at different time points. Fig 3.24
shows that the lipid coating did not increase MIL-88A(Fe) uptake by macrophages.
Instead, the uptake of non-coated particles was significantly higher than coated ones. The
lipid mixture did not contain M.tb-specific lipids or macrophage targeting ligands. In
addition, the positively charged bare-MIL-88A(Fe) could have a more robust interaction
with the cell membrane than negatively charged coated particles. The other two lipidcoated MIL-88A(Fe) studies did not conduct cell uptake for coated and non-coated
particles[287, 288]. However, one group that developed lipid-coated MIL-100(Fe) (Lip-
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MOF) did investigate the impact of lipid coating on uptake by comparing the uptake at
37°С and 4°С in Hela cells[290]. They found out the Lip-MOF showed a significant
reduction in uptake at 4°С, whereas the uptake of uncoated MOF was not significantly
decreased at reduced temperature. Nevertheless, there was no evidence showing that the
uptake of Lip-MOF was significantly higher than uncoated MOF.
Next, we evaluated cell uptake for more M.tb specific lipid-coated MIL-88A(Fe)
formulations. MA and self-extracted lipids were included in the coating. Korf et al.
incorporated purified MA from the cell wall of M.tb into liposomes[315]. These MAliposomes were phagocytosed by peritoneal macrophages and elicited innate immune
responses. Lemmer et al. developed MA-PLAG nanoparticles via a double emulsion
solvent evaporation method[212]. The inclusion of MA into PLGA significantly
increased phagocytic uptake of nanoparticles by macrophages. As shown in Fig 3.25,
MA-containing lipid-coated groups exhibited a slightly higher uptake than the control,
and a higher percentage of MA also induced higher uptake during the period (not
significantly). Of note, lipid-coated MIL-88A(Fe) containing extracted lipids from
M.avium induced a significant greater cell uptake. In the extracted lipids, besides MA,
there are many other lipids or components from cell wall components which could be
involved and contribute to cell recognition and uptake process.
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Figure 3.23 Inhibitory study of endocytic pathways of lipid coated MIL-88A(Fe)-Cy5 in
3D4/21 cells. Data are shown as means ± SEM, ***p < 0.001 (one-way ANOVA
followed by Dunnett test).

Figure 3.24 Cellular uptake of MIL-88A(Fe) and lipid-coated MIL-88A (Fe) particles by
3D4/21 swine alveolar macrophages.
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Figure 3.25 Cellular uptake of different lipid-coated MIL-88A(Fe) by 3D4/21 swine
alveolar macrophages. X: extracted lipids from M.avium; MA: mycolic acid from SigmaAldrich. Data are shown as means ± SEM, ***p < 0.001 (one-way ANOVA followed by
Dunnett test).
3.4 Conclusions
In this chapter, the M.tb-mimicking drug delivery system for TB infection was developed
by mimicking the shape, size, and cell membrane of M.tb. The synthesized MIL-88A(Fe)
particles were rod-shaped and positively charged with the size of (2.6±0.2) × (0.6±0.1)
μm. MIL-88A(Fe) particles were stable in PBS and cell medium for over a week,
whereas nearly half of particles decomposed in bacteria medium. MOFs did not have
intrinsic bacterial killing activity in the extracellular study. MIL-88A(Fe) was coated with
lipids, including DPGG, PC, Chol, and MA, to mimic the cell wall of M.tb. The coating
involved two steps: 1) direct coordination of phenolic lipids (DPGG) on the surface of
particles to provide a platform for secondary coating; 2) hydrophobic interaction of other
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lipids with DPGG-coated particles. TEM-EDX and negatively surface charge confirmed
the successful coating of lipids on MOFs.
MET as a model HDT agent was encapsulated via the modified nanoprecipitation method.
Drug loading analyzed by HPLC was 12%. EDX confirmed the existence of the drug in
biomimetic MIL-88A(Fe) particles after the coating process. TLC and IR determined
extracted lipids from M.avium. Visualized by fluorescence microscopy, the azidemodified trehalose analogs of M. avium labeled with alkyne-functionalized dye were
confirmed. The internalization mechanisms and cell uptake kinetics of the bacteriamimetic particles were studied in the non-infected alveolar macrophage cell model.
Increased cell uptake was observed in particles with M.tb specific lipids. The group using
extracted lipids from M.avium exhibited considerably higher uptake compared to the
groups treated with lipid-coated particles with commercial MA and the control group.
Phagocytosis was still the major endocytic pathway involved in the internalization of
lipid-coated particles. Overall, lipid-coated MIL-88A(Fe) with bacterial lipids, which are
designed to mimic the physical and biological features of M.tb, is a promising candidate
to target the macrophages to deliver HDT in TB infection.
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Chapter 4 Curdlan- MIL-100 nanoparticles for TB
4.1 Introduction
In recent years, the appreciation of host-directed therapy using immunomodulators to
achieve better control of TB has considerably increased[130, 316-318]. M.tb,
phagocytized by macrophages, can reside and replicate in the phagosomes of
macrophages. The infected macrophages trigger the release of pro-inflammatory
cytokines and chemokines, which help to activate the T cell responses. Therefore,
delivering the immunomodulatory signal to the infected cells may stimulate the immune
system, particularly macrophages, to kill intracellular bacteria through self-defense
mechanisms.
Curdlan, a bacterial polysaccharide (β-1,3 glucan) produced by Rhizobium,
Agrobacterium, and Alcaligenes faecalis, possesses anti-tumor, anti-inflammatory, antiinfective, and immunomodulatory properties[319-322]. Curdlan can be recognized by the
dectin-1 receptor expressed on dendritic cells and macrophages[323, 324]. Therefore,
many studies used curdlan as ligands in the targeting delivery system[321, 325, 326].
Dectin-1 signal contributes to various cellular activities, including phagocytosis,
regulation of the expression of inflammatory cytokines, and modulation of host immune
responses[327]. Lee et al. showed activation of Dectin-1increased ROS production, proinflammatory cytokines, and antimicrobial activities against intracellular M.tb growth in
A549 cells[328].
Dude et al. previously described immunomodulatory nanoparticles for infectious
diseases[329]. This multimodal nanoparticle composed of curdlan adsorbed on the
surface of a chitosan shell and PLGA Core could stimulate pro-inflammatory cytokine
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and intracellular reactive oxygen and nitrogen species (ROS/RNS) in the alveolar like
macrophages. The same group later reported that curdlan-conjugated PLGA
nanoparticles(C-PLGA-NPs)were non-toxic to cells, enhanced ROS/RNS production,
toxic to intracellular pathogens, and functioned as a sustained anti-TB drug release
system[330]. Basha et al. demonstrated dual anti-TB drugs complexed with cyclodextrin
and conjugated to curdlan nanoparticles to target infected macrophages[321].
Several studies have reported using MIL-100(Fe) as anti-TB drug delivery systems. Ironbased MOF, MIL-100 (Fe), has been reported as an isoniazid(INH) delivery system with
a good controlled-release profile[141]. Another example described the MIL-100(Fe) on
3D porous diatoms as carriers for INH exhibiting the drug release up to 23 days[331].
Panda et al. investigated the effects of structural parameters (pore volume and surface
area) of MIL-100(Fe) on the loading of the anti-TB drug, Rifampicin[332].
This chapter aims to investigate the method to incorporate curdlan onto the MIL-100(Fe)
nanoparticles, which could further function as an immunomodulating anti-TB drug
delivery system.
4.2 Material and methods
4.2.1 Synthesis and characterization of MIL-100(Fe)
In this chapter, MIL-100(Fe) was used the same batch synthesized by a microwaveassisted solvothermal method (See Chapter 2, Section 2.2.1.1). Characterization of MIL100(Fe) was completed in Chapter 2.
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4.2.2 Stability of MIL-100(Fe)
4.2.2.1 Extracellular stability of MIL-100(Fe)
The stability of MIL-100(Fe) particles was determined in different biological media by
assessing the disassociated iron using a colorimetric method[281]. MIL-100(Fe) particles
(1 mg∙mL-1) were incubated in PBS, cell medium, and bacteria medium for 2h,6h,12h,
24h, 3 days, and 7 days. Samples were centrifuged at 20,000×g for 20 min.
In a well of 96-well plate, 10 μL of a sample or FeCl3 standard solutions
(0.1,0.15,0.3,0.5,0.75,1,1.5, 2 mM) were mixed with 75 μL of 1 M acetic buffer (pH 4.5)
with 120 mM of thiourea (Sigma), and 25 μL of a solution containing 240 mM ascorbic
acid (ACROS Organics), 3 mM Ferene S (Sigma), and 120 mM of thiourea. The optical
density measurement at 595 nm was performed using Synergy H4 Multi-Mode
Microplate Reader (Bio-Tek, Winooski, VT) after 1 h upon mixing the reagents.
4.2.2.2 Intracellular stability of MIL-100(Fe)
The intracellular stability of MIL-100(Fe) was evaluated on 3D4/21 cells and A549 cells.
10 μg∙mL–1 of particles were incubated in the cells for 8, 18, and 24 h. The sample
preparation method was based on previously published protocol[282]. Details were
described in Chapter 3, Section 3.2.3.1. Iron detection followed the same procedure
described above.
4.2.3 Cell culture
3D4/21 swine alveolar macrophages (ATCC, CRL-2843) were cultured in RPMI 1640
medium containing 2 mM L-glutamine and supplemented with 10 mM HEPES, 1.0 mM
sodium pyruvate (Gibco), 1% PenStrep, 90% 0.1 mM nonessential amino acids (Gibco),
and 10% fetal bovine serum (FBS; Corning).
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4.2.4 Development of curdlan-conjugated MIL-100(Fe) particles
The procedure for conjugation of curdlan to carboxylated MIL-100(Fe)(MIL-100(Fe)COOH) was adopted from Tukulula et al. [330]. 5mg curdlan (Sigma) was suspended in
1mL anhydrous DMF (Fisher) and heated at 60°C under N2 atmosphere until dissolution.
MIL-100(Fe)-COOH (10 mg) and NHS (~5 mg; Thermo Scientific) was stirred in water
(1 mL). EDC.HCl (~3mg; Thermo Scientific) and DIEA (5µL; ACROS Organics) were
added and then reacted for 2 h. Then the curdlan-DMF solution was added to the 1 mL
EDC-activated MIL-100(Fe-COOH solution and the resultant mixture was further stirred
at room temperature for 48 h. After this time, the solvent was removed under
centrifugation at 10,000 g for 10 min, and particles were washed successively with water
to remove the carbodiimide chemistry byproduct. The resulting curdlan-conjugated MIL100(Fe) conjugate was then obtained lyophilized.
4.2.5 Characterization of curdlan-conjugated MIL-100(Fe)
4.2.5.1 Fourier transform infrared spectroscopy (FT-IR)
The structural characterization of curdlan-conjugated MIL-100(Fe) was conducted on
Nicolet 380 FT-IR spectrometer (Thermo Scientific Corporation). The sample was placed
on a diamond crystal plate at room temperature. Each spectrum was scanned in the
spectral region of 4000–500 cm−1.
4.2.5.2 Quantification of curdlan
The fluorescence dye-binding micro-assay was used for curdlan quantification [333].
Sample (~1 mg) was prepared from destroying curdlan-conjugated particles in100mM
citrate buffer. The curdlan standard solutions or samples were prepared in 1 N NaOH. 30
µL of 6N NaOH was added into 300 µL of standard, incubating at 80 °С for 30 min. A

119
630 L dye of aniline blue mix was added. The mix was prepared with 40 volumes of 0.1%
aniline blue in water, 21 volumes of 1 N HCl, and 59 volumes of 1 M glycine/NaOH
buffer, pH 9.5.
4.2.6 Curdlan-coated MIL-100(Fe) particles
Curdlan-MIL-100(Fe) particles were prepared by co-precipitation method adapted from
Basha. R.Y, et al.[321]. 20 mg MIL-100(Fe) and 1 mg curdlan were added in 2 mL
formic acid (Fisher Scientific). Curdlan and MIL-100(Fe) were mixed thoroughly under
bath sonication for 10 mins. The mixture was then added dropwise to 20 mL water
containing 1% pluronic F-127 (Sigma) under probe sonication. Curdlan-MIL-100(Fe)
particles were precipitated due to the solvent change. The particles were washed with
ethanol twice and water three times and lyophilized.
4.2.7 Degradation of curdlan
According to a previous study, the degradation of curdlan was prepared by hydrolysis
using hydrogen peroxide under modified conditions [334]. Curdlan (Sigma) was
dissolved in 2 N, NaOH in a concentration of 2%(w/v). H2O2 (30% wt, ACROS Organics)
was added, and the reaction was kept in a water bath at 65 °C for 40 min. To precipitate
the hydrolysates, the equal volume of 2N, HCL was added into the mixture. The resulting
flocculation was centrifuged, washed with water three times to remove the salts, and
lyophilized. The degradation process was repeated followed the same process above.
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4.2.8 Characterization of digested curdlan
4.2.8.1 Fourier Transform Infrared Spectroscopy (FT-IR)
The structural characterization of breakdown curdlan was conducted on Nicolet 380 FTIR spectrometer (Thermo Scientific). Sample (curdlan and breakdown curdlan) was
placed on a diamond crystal plate at room temperature. Each spectrum was scanned in the
spectral region of 4000–500 cm−1.
4.2.8.2 13C and 1H nuclear magnetic resonance
Curdlan and breakdown curdlan were analyzed by 13C and 1H NMR using a Bruker
Avance 600MHz solutions spectrometer (Bruker Instruments, Inc.). Samples were
dissolved in d6-dimethyl sulfoxide (d6-DMSO, Sigma).
4.2.8.3 Water dispersion of curdlan and digested curdlan
1 mg curdlan and digested curdlan were added into small glass vials containing 10 mL
water. The suspensions were bath-sonicated for 10 mins. The water dispersion of curdlan
and its breakdown were observed.
4.2.9 Characterization of curdlan-coated MIL-100(Fe)
4.2.9.1 Dynamic light scattering (DLS)
The size and zeta-potentials of Curdlan-coated MIL-100(Fe) were determined using
Zetasizer, Nano-ZS (Malvern). Prior to analysis, particles were suspended in distilled
water at 50µg∙mL-1 and sonicated under ultrasound for 10 min.
4.2.9.2 Scanning electron microscopy (SEM)
The morphology of the lyophilized curdlan-coated MIL-100(Fe) and MIL-100(Fe)
particles was examined on Hitachi S-3400 scanning electron microscope (Hitachi, Japan)
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at an accelerating voltage of 5 keV. Samples were placed onto aluminum specimen stubs
and then sputter-coated with gold prior to imaging.
4.2.9.3 Differential scanning calorimetry (DSC)
Thermal properties of samples were characterized by the differential scanning calorimeter
(DSC-Q2000, TA Instruments-Waters LLC) under N2 atmosphere. Curdlan, digested,
curdlan-MIL-100(Fe), and MIL-100(Fe) were accurately weighed and added into sliver
pans. Samples were heated at a rate of 5 °C / min from 20 °C to 400 °C.
4.2.9.4 Intracellular stability
The stability of curdlan-coated MIL-100(Fe) in 3D4/21 cells was also determined to
compare with non-coated MIL-100(Fe). The procedure was described in Chapter 3,
Section 3.2.3.1.
4.3 Results and discussion
4.3.1 Stability of MIL-100(Fe)
MIL-100(Fe) stability was evaluated in PBS, 3D4/21 cell medium, and 7H9 bacteria
medium. Samples from different time points were collected and analyzed. The
colorimetric assay was used to determine the disassociated iron in the medium[281]. The
result is shown in Fig 4.1. MIL-100(Fe) was very stable in PBS and cell medium for up
to a week. However, Horcajada et al. reported that MIL-100(Fe) nanoparticles undergo a
progressive degradation in PBS[137]. 14% of the total amount of the organic linkers in
particles was disassociated from MIL-100(Fe) after 5 days. Then particles had a drastic
58% degradation after 7days.
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MIL-100(Fe) in bacteria medium exhibited a gradual degradation with about 40% loss of
total iron weight in particles, similarly, observed in MIL-88A(Fe). Sodium citrate and
ferric ammonium citrate in bacterial medium-7H9 broth are excellent chelating agents.
These salts’ interaction with the MOFs slowly replaces the carboxylate linkers to form a
citrate-Fe3+ complex, leading to the progressive degradation of the MOFs.

Figure 4.1 The degradation profile of MIL-100(Fe) in PBS, cell medium, and bacteria
medium at different time points. Data are shown as mean ± SEM. Each measurement was
carried out in triplicate.
4.3.2 Development and characterization of curdlan-conjugated MIL-100(Fe)
The curdlan-conjugated MIL-100(Fe)was carried out through carbodiimide chemistry,
EDC/NHS-mediated ester formation. The carboxyl groups of MIL-100(Fe) were
activated by the addition of EDC and NHS and then reacted with the functional hydroxyls
on the curdlan. Tukulula et al. demonstrated the conjugation of curdlan on PLGA with -
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COOH terminal and the use of the synthesized copolymers in nanoparticles
formulation[330]. Lehtovaara et al. described the synthesis of curdlan-graftpoly(ethylene glycol)(PEG)copolymers through carboxylated PEG to the hydroxyl
groups of the curdlan backbone[335]. The IR spectrum shows that the product shared
~1600 cm-1(-C

O), ~1380 cm-1(-C-O) with MIL-100(Fe), and ~1000 cm-1 (C–O–C)

with curdlan (Fig 4.2). However, IR cannot confirm the successful conjugation but can
confirm the presence of curdlan in MIL-100(Fe).
Next, a fluorescent dye, aniline blue, was used to label 1,3-β-glucan. Curdlan and
other1,3-β-glucan form right-handed triple helices[336]. Then treatment of the triplehelix glucans with NaOH produces single-helix conformers, preferentially reacting with
aniline blue in solution[337]. The stable bound form of aniline blue-curdlan complexes
exhibits fluorescence. The equation from the standard curve of curdlan is
Y=0.8803x+4.6094. The amount of curdlan was 1.6% (curdlan/ formulated particles,
w/w). Another issue according to this method is the solubility of curdlan in DMF. Even
with the addition of DMSO in DMF with heating, it cannot completely dissolve curdlan.
Therefore, large particles were observed after resuspending into the water, which could
be due to the undissolved curdlan attached to particles interacting with other particles
(Data are not shown).
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Figure 4.2 The FT-IR spectrum of the curdlan, MIL-100(Fe), and curdlan-conjugated
MIL-100(Fe).
4.3.3 Degradation and characterization of curdlan
Curdlan is a linear chain homopolymer of d-glucose linked β-(1 → 3). Curdlan is
insoluble in water due to the extensive intra/intermolecular hydrogen bonds, but it can
dissolve in alkaline, acidic, and dimethyl sulfoxide (DMSO). Therefore,
nanoprecipitation could be used to prepare curdlan-coated nanoparticles. First, the natural
curdlan and MIL-100(Fe) (1:10 w/w) were dissolved in formic acid with vortex. They
were added under probe sonication to water containing 1% pluronic F-127, which serves
as a stabilizer of particles, resulting in the stable single-particle suspension. Changing the
solvent led to the precipitation of curdlan on nanoparticles. However, a large number of
aggregates were observed (Fig 4.3a) after resuspending the curdlan-coated MIL-100(Fe)
into the water. The size distribution of particles was presented in Fig 4.3b. The z-average
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was 2921 nm, whereas the size of MIL-100(Fe) was 300 nm. The long linear chain of
curdlan on particles interacts with other chains through hydrogen bonds, forming
aggregations. Next, a shorter and more water-soluble curdlan was prepared by hydrogen
peroxide degradation. In Fig 4.4, the natural curdlan is not water-soluble, with many
large flakes floating. After curdlan experienced the first degradation, the water
dispersion of curdlan improved, the size of aggregates decreased significantly. After
being hydrolyzed twice with H2O2, curdlan was well dispersed in the water.

Figure 4.3 (a)Curdan-MIL-100(Fe) in water before and after vertex; (b) size distribution
of curdlan-MIL-100(Fe).
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Figure 4.4 Water dispersion of curdlan and once- and twice-digested curdlan. DC:
digested curdlan.
The FT-IR and NMR were carried out to determine the chemical structure of curdlan and
its digested products. Ideally, this procedure only changes the molecular weight of
curdlan and will not create new functional groups. Alternat ion of curdlan structure may
affect its biological activities. The FT-IR spectrum shows peaks across three samples at
~3300 cm-1(-OH), ∼1400 cm−1 (symmetrical deformation of –CH3 and –CH2), and
∼1035 cm−1 (stretching vibration of the C–O–C in glucose circle) (Fig 4.5). No
distinctive peak was shown up in the degradation products. However, Wu et al. reported
hydrolysates of curdlan using H2O2 exhibited the new bands at ~1720 cm-1 indicated to
the carboxylic group[334].
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Figure 4.5 FT-IR spectrum of the curdlan and once- and twice digested curdlan.
The NMR fingerprint of the original curdlan correlated with the literature[330, 335]. 6
carbon positions in curdlan backbone rings can be seen as separately distinct peaks.
Compared to the 13C-NMR spectrum of curdlan, there is no new peak in the digested
curdlan (Fig 4.6). It is indicated that the digested curdlan still maintains the same carbon
backbone as the original curdlan. The 1H-NMR spectrum reveals no new peaks, and the
chemical shifts are the same in both original and digested curdlan (Fig 4.7). Overall,
using the H2O2 treatment with optimized conditions to prepare a water-soluble low
molecular weight curdlan would not alter its chemical structure.
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Figure 4.6 The 13C NMR spectrum of Curdlan and digested Curdlan in d6-DMSO.

Figure 4.7 The 1H NMR spectrum of Curdlan and digested Curdlan in d6-DMSO.
4.3.4 Characterization of curdlan-coated MIL-100 (Fe)
As the structure of the digested curdlan was verified, instead of using the original waterinsoluble curdlan, the digested curdlan was used to prepare curdlan-coated MIL-100(Fe).
The size of curdlan-coated MIL-100(Fe) measured by DLS was about 2µm (Fig 4.8).
However, the size of non-coated MIL-100(Fe) was 300nm (Chapter two, Fig 2.7a). SEM
images show no significant morphological changes before and after the curdlan coating
(Fig 4.9). The increase in the hydrodynamic size of curdlan-coated particles suggests the
presence of an external hydration sheath due to the curdlan coating.
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To confirm the interactions between curdlan and MIL-100(Fe), DSC was performed for
curdlan, digested curdlan, MIL-100(Fe), and curdlan-MIL-100(Fe). As shown in Fig 4.10,
MIL-100(Fe) exhibits two sharp endothermic peaks (melting peaks) at 354 °C and 374 °C
indicating the two crystalline structure forms of MIL-100(Fe). Curdlan-coated MIL100(Fe) also had two endothermic peaks, with one peak shifting to 225 °C. This indicates
the curdlan interacted with MIL-100(Fe) surface, leading to the change in its thermal
properties. Curdlan and digested curdlan did not reveal any distinctive peaks in the
temperature range. The intracellular stability of curdlan-coated MIL-100(Fe) was
conducted in 3D4/21 cells for 24 h period. The evaluation of MOF stability was followed
by quantifying the accumulative release of the iron. The curdlan coating conferred
enhanced stability. The degradation profile in Fig 4.11 shows curdlan-coated MIL100(Fe) had 16% of the total amount of iron in the particles releases, whereas bare MIL100(Fe) lost 32%. Based on DSC and stability study, we can confirm the curdlan was
coated on the surface of MIL-100(Fe).

Figure 4.8 The size distribution of MIL-100(Fe).
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Figure 4.9 The SEM images of (a) MIL-100(Fe) and (b)curdlan-coated MIL-100(Fe)
under the magnification of 5k and 10k.
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Figure 4.10 The DSC curve of Curdlan, digested curdlan, MIL-100(Fe), and curdlancoated MIL-100(Fe).
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Figure 4.11 Intracellular degradation of MIL-100(Fe) and Cur- MIL-100(Fe) in
3D4/21cells at different time points. Data are shown as mean ± SEM. Each measurement
was carried out in a quadruplicate. Cur- MIL-100(Fe): Curdlan-coated MIL-100(Fe).
4.4 Conclusions
In this chapter, two methods of preparing MOF particles with curdlan were explored. The
success of the conjugation method needs to be studied in more detail. However, the
water-soluble issues retard this method moving forward. We developed curdlan-coated
MIL-100(Fe) using nanoprecipitation, which was adopted from preparing curdlan
nanoparticles. In order to solve the water dispersion issues with the curdlan, we
successfully digested the curdlan into short chains using the hydrogen peroxide method.
The FTIR and NMR spectrums can confirm that this degradation approach did not disrupt
the chemical structure of curdlan. There were no significant morphology changes in
coated-MIL-100(Fe) from SEM images. The endothermic peak shifted in curdlan-coated
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MIL-100(Fe) compared to the meting peak in MIL-100(Fe), indicating the surface
interaction between curdlan and MIL-100(Fe). The curdlan coating improved the stability
of MOFs as the release of iron decreased in coated particles. The curdlan-coated MIL100(Fe) could be potential immunomodulating particles whose biological activities need
to be carried out in the future.
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Chapter 5 Conclusions and Future directions
5.1 Conclusions
Tuberculosis (TB) is the world’s leading infectious disease caused by Mycobacterium
tuberculosis which most commonly affects the lungs. Although TB is preventable and
curable, approximately 10 million people fall ill every year, and 1.5 million people die
from TB. Current standardized treatment regimens are very lengthy, including 3 to 6
drugs for at least 6 months. This prolonged anti-TB therapy leads to patient nonadherence
and the ongoing emergence of drug-resistant - M.tb strains. There is a great need for new
treatment approaches.
The principal objective in this work was to engineer the particles that mimic
physicochemical and biological properties of bacteria, resulting in enhance recognition
and uptake by macrophages. One promising approach is host-directed therapies (HDTs)
to enhance the host immune responses to kill the bacteria rather than targeting the
bacterium itself; therefore, drug resistance could be avoided. Chapter 2 was the proof-ofconcept for developing general “pathogen-like” particles, whereas Chapter 3&4 were
M.tb-specific.
Metal-organic framework (MOFs), a novel hybrid porous material composed of metal
nodes and organic linkers, has become a promising platform for this biomimetic
application due to its outstanding characteristics, including high porosity and large
surface area adjustable pore size, easy modification. In this work, we used carboxylated
iron-based MOFs, namely MIL-100(Fe) and MIL-88A(Fe). MIL-100(Fe) is spherical,
and nanoscale whereas MIL-88A(Fe) is rod-shaped and micro-sized. They are non-toxic
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(MTT assay), and stable in PBS and cell medium (Degradation study) materials. They
process versatile surface functionality due to their organic linker molecules.
We first developed mannose-functionalized MOFs as many pathogens expressed
mannose which mannose receptors can recognize on macrophages. MIL-88A(Fe) and
MIL-100(Fe) particles were successfully synthesized and modified with mannose via an
amine-carboxylic acid coupling reaction. We found that the macrophage uptake of
mannose-modified MIL-88A(Fe) significantly increased compared to non-modified
particles. MIL-100(Fe) without mannosylation already exhibited considerably fast and
high uptake; therefore, the mannose modification did not affect its uptake. Phagocytosis
was the major endocytic pathway involved in MOF particle uptake. Endocytosed
particles were observed to accumulate in acidic compartments where many pathogens are
known to reside and survive. Therefore, there is a potential to use MOFs as a delivery
system to target intramacrophagic pathogens.
As the surface modification in large and rod-shaped particles positively impacts uptake,
we modified MIL-88(Fe), which is of similar shape and size to M.tb, to mimic bacteria as
host-direct therapy(HDT) delivery system for the treatment of TB. We developed the
MIL-88(Fe) hybrid coating system to mimic the M.tb cell wall, including the inner layer
of phenolic lipids and outer mixed lipids containing mycolic acids. We found that the
uptake of MIL-88A(Fe) coated with extracted bacterial lipids significantly increased.
Lipid coating did not change the endocytic pathway of the internalization of particles.
Metformin as a model HDT agent was encapsulated in MIL-88A(Fe) via the modified
nanoprecipitation method with 12% drug loading.
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On the other hand, MIL-100(Fe) itself without surface functionalization exhibited high
macrophage uptake, so MIL-100(Fe) modification with curdlan was not to improve the
uptake but be expected to show immunomodulating activity. We investigated two
methods to develop curdlan-coated MIL-100(Fe). To improve the water dispersion of
particles, we used the digested curdlan rather than the original curdlan to coat on MIL100(Fe). FTIR and NMR confirmed the chemical structure of the digested.
In summary, iron-based MOFs are good candidates to develop bacteria-mimicking
delivery systems. Modification of MIL-88A(Fe) with biological components from
bacteria showed a promising macrophage target. M.tb mimicking MIL-88A(Fe) as
metformin delivery system had a reasonable drug loading which still needs further
improvement. MIL-100(Fe) can also be easily modified with bacterial components
(mannose and curdlan). MIL-100(Fe) were readily taken by macrophages, so ligands
modification did not significantly increase uptake. The immunomodulation activity of
curdlan-coated MIL-100(Fe) will be investigated in the future.
5.2 Future directions
This dissertation mainly focused on the development of pathogen-like delivery systems to
target macrophages. However, achieving good drug loading was still a challenge,
particularly for small and hydrophilic molecules. Identification of an ideal HDT agent
will be the first focus. Drug candidates should have a proper size that allows them to
enter the particles via the pore. During the lipid coating process, many drugs were lost
due to their small size and hydrophilicity. The functional groups of candidates that can
interact with MOFs via non-covalent bonds may help improve the drug loading and
prevent the pre-mature release of drugs. Despite low drug loading, metformin used in this
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work is still a strong candidate due to its low cost and evidence of efficacy and safety in
TB patients. Two potential strategies have been proposed to obtain higher drug loading
and a controlled release profile. First, a different type of MOF, MIL-53(Fe), made of iron
(III) and 1,4-dicarboxylic acid, can be used as a delivery system for metformin.
Second, metformin can be combined with iron (III) and fumaric acid (MIL-88A(Fe)) as a
part of the constituent of MOF. Like MIL-88A(Fe), MIL-53(Fe) also displays a typical
bipyramidal hexagonal prism structure (Fig 5.1) [1]. MIL-53(Fe), which is more stable
and has a larger pore size than MIL-88A(Fe), is expected to have higher drug loading and
a slow-release profile. Vahed at el. described MIL-100(Fe)-metformin system where
metformin like trimesic acid served as an organic linker[294]. Since metformin is a part
of the synthesized MOF structure, the MOF contains a large number of drug molecules,
which highly increases drug loading compared to the direct encapsulation method.

Therefore, there is a potential to develop the MIL-88A(Fe)-Metformin system.
Figure 5.1 TEM image of MIL‐53(Fe). Adapted from reference[338].
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We expect these bacteriomimetic particles to work as HDT drug delivery carriers and act
as immunomodulatory compounds that could activate host cells and further stimulate
immune responses. The next plan will explore alveolar macrophage activation status after
exposure to the M.tb-mimicking HDT drug delivery system in both infected and noninfected cell models. Different biomarkers can determine activation status for M1 and M2
identification. The expression of inflammatory cytokines can be evaluated by EALSA or
real-time polymerase chain reaction (RT-PCR). The intracellular bacteria-killing activity
of empty-and HDT-loaded M.tb mimicking particles will be assessed in M.avium and
M.smegmatis infected macrophage models.
The cellular trafficking of bacteria and particles is needed to understand the interaction
between particles, bacteria, and macrophages. Therefore, the initial step will be to
transfect M.tb to express a GFP. The next step is to have bacterial cell membrane
components such as lipoproteins become fluorescent-labeled. This is because we
extracted the modified lipids from mycobacteria to coat on the MOFs to allow the
particles to become fluorescent.
Developing personalized bacteria-mimicking particles for TB treatment will be one of the
future directions. The strategy will be to extract lipids from patients isolates and
formulate specific bacteria-mimicking delivery systems, which may improve therapeutic
effects, particularly for drug-resistant TB patients.
Curdlan-functionalized polycaprolactone (PCL) nanoparticles were showed to activate
macrophages and induce killing of intracellular M.tb. Therefore, the antimicrobial
activity of curdlan-MIL-100(Fe) particles needs to be investigated both extracellularly
and intracellularly.
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